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ABSTRACT
Bacterial quorum sensing is regarded as a novel target for the design of antimicrobials. Based on
lead structures identified from HTS, 39 analogues have been synthesized and evaluated in Vibrio haveyi.
Potent inhibitors with IC50 values at single‐digit micromolar concentrations for AI‐2 mediated quorum
sensing have been identified. On the second project, post‐synthesis modifications of DNA provide easy
functionalizations for expanded applications such as aptamer selection. A CBT‐modified thymidine ana‐
logue (CBT‐TTP) has been synthesized and used for enzymatic incorporation into DNA. Post‐synthesis
modifications through condensation with 1,2‐aminothiol for installation of a boronic acid moiety or a
fluorophore have been achieved. On the third project, H2S has been recognized as an important gas‐
otransmitter and its concentration is relevant to a variety of diseases. A novel fluorescent probe (DNS‐Az)
has been developed for quantitation of H2S in aqueous solutions. This probe has been used to measure
H2S concentrations in the blood.
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DESIGN AND SYNTHESIS OF NOVEL SMALL‐MOLECULE INHIBITORS OF BACTERIAL QUORUM SENS‐

ING
Abstract:
The development of new antimicrobial agents is of great importance due to the evolution of drug
resistance. Bacterial quorum sensing has received much attention in recent years because of its rele‐
vance to pathological events such as biofilm formation and virulence factor expression. Based on the
structures of two lead inhibitors (IC50: 35‐55 µM) against AI‐2 mediated quorum sensing identified
through virtual screening, we have synthesized 39 analogs and examined their inhibitory activities.
Twelve of these new analogs showed equal or better inhibitory activities compared with the lead inhibi‐
tors. The best compound showed an IC50 of about 6 µM in a whole cell assay using Vibrio harveyi as the
model organism. The structure‐activity relationship has been discussed.
1.1
1.1.1

Introduction
Bacterial quorum sensing pathways
It is known that bacteria can coordinate community wide activities upon environmental stimula‐

tion, behave like multi‐cellular organisms in some sense, and thus adapt themselves to the changing en‐
vironmental conditions by taking advantage of an intercellular communication process known as quor‐
um sensing. Quorum sensing is regulated by the production and detection of small signaling molecules
called autoinducers (AIs).1‐3 When the environmental concentration of AIs, which is correlated to the
bacterial population density, reaches a certain threshold, quorum sensing is activated. The activation of
AI receptors can then modulate the expression of a variety of genes and consequently control the be‐
havior of bacterial processes such as bioluminescence,4 biofilm formation, virulence factor expression,5, 6
conjugation,7 sporulation,3 and swarming motility.8

2
Several major types of small molecules are used as autoinducers in bacterial quorum sensing. For
instance, acyl homoserine lactones (AHLs) are mostly used by Gram‐negative bacteria2 and autoinducing
peptides (AIPs) are used in Gram‐positive bacteria.9 Among all autoinducers reported, autoinducer‐2 (AI‐
2) seems to mediate quorum sensing in a remarkably wide range of bacteria including Gram‐negative
bacteria, such as H. influenzae, V. harveyi, E. coli, and S. typhimurium, and Gram‐positive bacteria, such
as B. subtilis, B. anthracis, and B. burgdorferi.10 As a result, it was proposed that AI‐2 could serve as an
“universal signal”, which affects interspecies communications among bacteria.10 The causative agent of
the disease cholera, human pathogen Vibrio cholerae, also possesses the AI‐2 mediated quorum sensing
pathway.11, 12 Related research has indicated that quorum sensing can control virulence factor expres‐
sion and biofilm formation in V. cholerae.11, 13
Because quorum sensing is involved in the regulation of pathologically relevant events, it is con‐
ceivable that inhibitors of quorum sensing could have therapeutic applications. In addition, selective
inhibition of quorum sensing pathways without killing bacteria is less likely to exert evolutionary pres‐
sure for bacteria to undergo rapid mutation and develop drug resistance. Furthermore, quorum sensing
inhibitors are important research tools in mechanistic studies. Recent years have seen an increasing in‐
terest in quorum sensing inhibitor/antagonist and agonist development.1, 3, 14‐33
1.1.2

Inhibition of AI‐2 mediated bacterial quorum sensing
AI‐2 mediated quorum sensing is observed in a broad range of bacteria, including Gram‐positive

and Gram‐negative bacteria. AI‐2 constitutes a group of compounds that can be inter‐converted to each
other upon hydration and binding with boric acid. The key intermediate in the biosynthesis of AI‐2, 4,5‐
dihydroxy‐2,3‐pentanedione (DPD, 4) is synthesized by enzymes MTAN (SAH/5’‐methylthioadenosine
nucleosidase or SAHN) and LuxS from S‐adenosyl‐L‐homocysteine (SAH).34 Scheme 2.1 shows the biosyn‐
thesis of AI‐2 and three examples of the AI‐2 family of compounds. SAH is hydrolyzed by MTAN to ade‐
nine and S‐ribosyl‐L‐homocysteine (SRH), which is then cleaved by S‐ribosylhomocysteinase (LuxS) to

3
form Hcy and DPD.35 Among the different forms of AI‐2, compound 5 is the active species in regulating
quorum sensing in V. harveyi through binding to its receptor, LuxP.34, 35

+

+H

-H
O
2

Scheme 1.1 Biosynthesis of DPD and different forms of AI‐2

Inhibition of AI‐2 mediated bacterial quorum sensing has been studied extensively. Inhibitors
against the AI‐2 pathway include those that target AI‐2 synthesis (MTAN or LuxS) and the AI‐2 receptor
(LuxP). Based on the structures of substrates to these important enzymes, SAH mimics such as immucil‐
lin‐A analogues have been reported as AI‐2 inhibitors targeting MTAN.33 SRH analogues have also been
reported as AI‐2 inhibitors targeting LuxS.

30, 36, 37

In the case of AI‐2, different forms of AI‐2 molecules

are used in different bacteria. For example, S‐THMF‐borate (Compound 5) is recognized by LuxP in V.
harveyi,34 and R‐THMF is recognized by LsrB in S. typhimurium and E. coli.38 Despite the universal func‐
tion of AI‐2 in bacteria, only a few inhibitors were reported for AI‐2 mediated bacterial quorum
sensing.26, 31, 32, 39 Based on the structure of AI‐2, our group has screened a series of boronic acids and
aromatic diols in V. harveyi. A group of single‐digit micromolar inhibitors have been identified, including
boronic acids 7‐1140 and pyrogallol analogues 12‐1641 shown in Figure 1.1.
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Figure 1.1 Boronic acids and pyrogallol analogues that inhibit AI‐2 mediated quorum sensing

1.1.3

Identification of lead AI‐2 inhibitors through virtual screening
Due to the fact that AI‐2 mediated quorum sensing regulates gene expression in a variety of bac‐

teria, the development of selective and potent inhibitors targeting the AI‐2 pathway would be of great
interest in both therapeutics and research purposes. The crystal structure of the AI‐2‐receptor (LuxP)
complex in V. harveyi has been solved by Bassler and co‐workers.34 In the crystal structure (Figure 1.2),
the borate moiety is bound to the positively charged side chains Arg 215 and Arg 310 through hydrogen
bonding. The hydroxyl groups of S‐THMF‐borate are stabilized by Trp 82 and Gln 77.

Figure 1.2 Crystal structure of LuxP complexed with AI‐2.
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A. Ribbon diagram of LuxP (PDB entry: 1JX6) complexed with ligand AI‐2 (S‐THMF‐borate, white
sticks) reproduced using the Pymol program;42 B. A schematic illustration of the interactions of S‐THMF‐
borate with LuxP reproduced by using the HBPLUS43 and the Ligplot program.44

Using this crystal structure of LuxP complexed with AI‐2, a previous study in our group was con‐
ducted to find small molecules that might bind LuxP and thus could act as AI‐2 inhibitors. Approximately,
1.7 million compounds from 14 commercial databases were screened by docking into the binding site of
LuxP. The top 1000 structures were then scored using a combination of ChemScore, PLP, ScreenScore,
ChemGauss, and ShapeGauss. 27 of the 42 hits resulted from the virtual screening were evaluated in a
whole‐cell based assay using V. harveyi as the model organism. Two lead structures (Figure 1.3), KM‐
03009 (16, IC50 35 µM) and SPB‐02229 (17, IC50 55 µM) were identified to exhibit potent inhibition while
showing no obvious cytotoxicity at concentrations twice that of their IC50 values. When re‐docked these
two structures into the binding site of V. harveyi LuxP, it was suggested that KM‐03009 could interact
with residues Ser79, Arg215, Thr266, and Arg310 through hydrogen bonding, and Tyr81, Trp82, Asn159,
Ile211, Phe206, and Ser265 through hydrophobic interactions. SPB‐02229 may form hydrogen bonds
with Asn159, Arg215, Thr266 and Arg310 and hydrophobic interactions with Tyr81, Trp82, Ile211,
Phe206, and Ser265, a similar pattern as observed for KM‐03009.

6

Figure 1.3 Proposed docking results of two lead compounds with V. harveyi LuxP AI‐2 binding site.
A. Structure of KM‐03009 and proposed docking interactions; B. Structure of SPB‐02229 and proposed
docking interactions.

The potency of compounds 16 and 17 determined through the whole‐cell based assay has con‐
firmed the successful discovery of inhibitors through virtual screening. The structures of these two com‐
pounds are unique and could be used as probes for mechanistic studies. In the current study, the struc‐
tures of these two lead compounds are analyzed and optimized for the design of a series of new antag‐
onists.

7
1.2
1.2.1

Results and discussion
Design and synthesis of analogues based on lead structures
In order to further improve potency and achieve an initial understanding of the structure‐

activity relationship, we have analyzed the structures of the two lead compounds (KM‐03009 and SPB‐
02229). Though these were not especially potent inhibitors, they represented the first AI‐2 inhibitors at
that time and the structural scaffold was novel and small, which allows for easy modification. In the
crystal structure of V. harveyi LuxP‐AI‐2 complex, the positively charged side chains of Arg 215 and Arg
310 were known to interact with three of the four borate oxygen atoms and thus stabilize the anionic
tetrahedral boron. The two hydroxyl groups and the furanoyl oxygen are also involved in hydrogen
bonding with Trp 82, Gln 77 and Asn 159. Compounds KM‐03009 and SPB‐02229 seem to interact with
LuxP by using the sulfone group at the position of the borate portion of the natural ligand. Specifically,
the two oxygen atoms of the sulfone group can interact with Arg 215 and Arg 310, mimicking the borate
oxygen atoms.45 The aryl ring is involved in some hydrophobic interactions. Based on these findings and
comparison of these two lead compounds with the other inactive hit compounds, it seems that the sul‐
fone group should be directly attached to an aryl group and the thioamide group should be separated
from the sulfone group by one atom.45 With the above information in hand, we were interested in modi‐
fying the structure of the two lead compounds by changing both ends (R1 and R2, Figure 1.4), while re‐
taining the middle skeleton of the structure. In addition, analogs were also prepared to examine the im‐
portance of the sulfone moiety (part B) and the thioamide/thioester structure (part C).

Figure 1.4 Optimization of the lead structure
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For part A of the structure (Figure 1.4), the following aryl groups were used: thiophenyl, pyridi‐
nyl, phenyl, or substituted phenyl groups including phenyl groups bearing a simple substituent or ex‐
tended by connecting to an additional aryl group. The impact of the polarity and the size of the substitu‐
tion on the phenyl group were studied. The effects of substituents at different positions (para‐ or meta‐)
of the phenyl ring were also explored. For Part B of the structure, the effect of changing the sulfone to a
sulfoxide group was examined. For part C, the influence of replacing the thiocarbonyl by a carbonyl
group was explored. In optimizing part D, the terminal functional group of the structure, different clas‐
ses of compounds were synthesized and compared, including amides, alkylamides, esters, acids, isoxa‐
zole and hydroxylamine (Schemes 1.2‐1.6).

Scheme 1.2 Synthesis of compounds 19‐21

Scheme 1.2 describes the synthesis of amide and thioamide compounds 19‐21. Specifically, aryl‐
sulfonyl amides (20) were synthesized in two steps from aryl thiols (18) and the corresponding α‐

9
haloacetamides through substitution in the presence of potassium carbonate under reflux, followed by
oxidation with oxone at room temperature.1 Thiation of arylsulfonyl amides (20) was accomplished by
using Lawesson’s reagent in THF 2 with yields in the range of 25‐60%.

Scheme 1.3 Synthesis of compounds 22‐26

The ester, thioester and acid analogs were synthesized as described in Scheme 1.3. Specifically,
the synthesis of arylsulfonyl esters (23) was very similar to that of arylsulfonyl amides (20) except for
that o‐xylene was used in the thiation reaction as the solvent instead of THF because esters are less re‐
active toward the Lawesson’s reagent and requires higher temperature.2, 3 The sulfonyl acetic acids (25)
were synthesized through hydrolysis of the corresponding methyl esters (23) at 50 °C under basic condi‐
tions. Arylsulfinyl acetate (26) was synthesized in high yield through the oxidation of arylthioacetate (22)
using m‐CPBA in DCM at 0 °C.4

10

Scheme 1.4 Synthesis of compounds 27 and 28

Compounds with extended phenyl rings were synthesized using the procedure shown in Scheme
1.4. Specifically, Suzuki coupling reaction was used for the addition of an extra aryl ring to give 27.5 Con‐
version of the ester group to a thioester (28) was accomplished using Lawsson’s reagent as described
above.

Scheme 1.5 Synthesis of compounds 31‐32
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Scheme 1.6 Synthesis of compounds 34‐38

Compounds 30‐32 and 34‐38 were synthesized using the procedures described in Schemes 1.5
and 1.6. The sulfonylmethyl isoxazoles (32) were synthesized in two steps from the reaction between
aryl thiols (18) and bromomethyl isoxazole (30) followed by oxidation using oxone. The synthesis of sul‐
fonyl N‐hydroxyethylamines (38) was completed in five steps. The substitution reaction between an aryl
thiol (18) and bromoacetaldehyde acetal (33) was accomplished in the presence of sodium ethoxide (1
equivalent). Acidic hydrolysis of the dimethyl acetal (34) yielded the aldehyde (35),6 which was then
converted to oxime (36). Sulfone (37) was prepared through oxidation using oxone and then the oxime
moiety was reduced to N‐hydroxyethylamine (38) using NaCNBH3 at room temperature.7
1.2.2

Evaluation of synthetic analogues in V. harveyi
All compounds synthesized were evaluated for their ability to inhibit AI‐2‐mediated quorum sens‐

ing following literature procedures.8‐12 In doing so, the MM32 strain of V. harveyi was used. As discussed
above, V. harveyi produces bioluminescence upon quorum sensing and the intensity of bioluminescence
is controlled by the level of AI‐2 stimulation.13 The MM32 strain lacks the LuxN receptor, which is re‐

12
quired to respond to AI‐112, and LuxS, which catalyzes the biosynthesis of DPD. Therefore, the biolumi‐
nescence can only be produced if a proper amount of DPD is added to the culture because there is no
endogenous AI‐2, and the level of AI‐1 does not interfere with the AI‐2 inhibition assay.
Inhibition of luminescence production by the synthesized compounds was studied in the pres‐
ence 5 µM of DPD, which was chosen to ensure that luminescence production stays in a sensitive region
as described previously.8 DMSO, which is used to dissolve the compounds for making the stock solutions,
was found to have significant influence on the bioluminescence.8 Therefore, a constant concentration of
DMSO (0.4% in volume) was maintained in the final test solutions so as to exclude its possible side effect
on the results. A 96‐well plate reader was used for the luminescence determination in an inhibitor con‐
centration range from 400 to 0 µM. The IC50 values were then calculated according to the inhibition
curves.
Since the MM32 strain does not respond to AI‐1, we also utilized the BB886 strain of V. harveyi,
which lacks the AI‐2 receptor, to test the AI‐1 inhibition activities of the synthesized compounds and to
check their selectivity toward AI‐2‐mediated quorum sensing. Before the inhibition test, the two strains
were checked for their specificity for AI‐2 and AI‐1 by incubation in the presence of boric acid/DPD and
cell‐free medium from MM32 (Lacks luxS enzyme which produces AI‐2), respectively. The results con‐
firmed that the MM32 strain did not respond to AI‐1 and the BB886 strain did not respond to AI‐2.
Among all the compounds tested, 12 compounds (Compounds 24a‐f, 23.g, 27a‐c, and 28a‐b) were ob‐
served to have significant inhibition activities against AI‐2 mediated quorum sensing with IC50 at or be‐
low 40 µM and 4 compounds (27a‐b, 28a‐b) have IC50 in the single digit micromolar range. Among the 12
active compounds, five compounds (24c‐d, 27a, 27c, and 28b) showed good selectivity towards AI‐2
with the IC50 values for AI‐1 inhibition above 200 µM.
In analyzing the AI‐2 inhibition results, we were interested in achieving some basic understanding
of the structural features, which are essential and/or beneficial for AI‐2 inhibition. The first thing that we
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examined was whether the thioamide structure (part C, Figure 1.4) was important. From the compounds
listed in Table 1.1, one can see that the “thio” structure feature was important for activity, but not es‐
sential. For example, the only difference between KM‐03009 and 20a was that one was the thioamide
(KM‐03009) and the other one was a simple amide. However, their activities differ by over ten‐fold with
the thioamide compound being more active. The situations are similar when comparing 20b vs. 21b, 20c
vs. 21c, and 20d vs. 21d.

Table 1.1 Structures and activities of amides and thioamides
Compound

R1 =

R2 =

X=

IC50 for AI‐2 (µM)

IC50 for AI‐1 (µM)

KM‐03009

Thiophen‐2‐yl

H

S

35±3

71±5

20a

Thiophen‐2‐yl

H

O

>400

‐‐

20b

Phenyl

H

O

>400

>400

21b

Phenyl

H

S

89±10

158±22

21c

Thiophen‐2‐yl

Ethyl

O

>400

>400

21c

Thiophen‐2‐yl

Ethyl

S

138±25

143±18

20d

Phenyl

Ethyl

O

>400

>400

21d

Phenyl

Ethyl

S

91±14

>400

Next we examined the comparison between thioesters and esters (Table 1.2). The same conclu‐
sions can be drawn, i.e., “thiation” is very important for AI‐2 activities in this series with the thioesters
having higher or equal activities compared with regular esters. For example, the only difference be‐
tween 23a and 24a is that 23a is an ester and 24a is a thioester and yet their IC50 values differ by about
6‐fold. The situations are similar when comparing between 23b and 24b, and 23c and 24c. However,
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there are also other cases, such as 23d vs. 24d and 23g vs. 24e, where the thioesters and the esters have
similar activities.

Table 1.2 Structures and activities of esters and thioesters
Compound R1 =

R2 =

X=

IC50 for AI‐2 (µM)

IC50 for AI‐1 (µM)

23a

Thiophen‐2‐yl

Ethyl

O

124±16

>400

24a

Thiophen‐2‐yl

Ethyl

S

22±2

54±6

23b

Phenyl

Ethyl

O

170±30

>400

24b

Phenyl

Ethyl

S

33±4

96±20

23c

Thiophen‐2‐yl

Isopropyl

O

127±21

>400

24c

Thiophen‐2‐yl

Isopropyl

S

34±2

>400

23d

Phenyl

Isopropyl

O

38±15

217±101

24d

Phenyl

Isopropyl

S

33±4

>400

23e

Thiophen‐2‐yl

Methyl

O

>400

>400

24f

Phenyl

Methyl

O

>400

>400

23g

4‐Bromophenyl

Ethyl

O

17±3

11±1

24e

4‐Bromophenyl

Ethyl

S

14±2

35±10

23h

4‐Bromophenyl

Methyl

O

81±3

115±35

23i

3‐Bromophenyl

Ethyl

O

163±22

319±23

23j

4‐Methoxyphenyl

Ethyl

O

87±6

79±15

24f

4‐Methoxyphenyl

Ethyl

S

26±4

33±4

23k

Propyl

Ethyl

O

>400

>400
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24g

Propyl

Ethyl

S

122±36

51±6

In comparing between esters and amides (Part D), higher inhibition activities of the ethyl and iso‐
propyl esters were observed compared to their corresponding amides. For example, thioesters 24a‐d
(Table 1.2, between 22 and 34 µM) have lower IC50 values compared to their corresponding thioamides
such as KM‐03009 (35 µM) and 21b‐d (around 100 µM), though it is hard to say whether some of these
small differences are meaningful given the intrinsic fluctuation of whole cell assay results. For the sub‐
stituents of part D of the ester series, there is essentially no difference between ethyl esters and isopro‐
pyl esters, but methyl esters are obviously weaker inhibitors. For example, compounds 23e and 23f are
inactive toward AI‐2. However, the same trend was not observed with the amide compounds. One thing
worth mentioning is that the isopropyl ester compounds (23c, d and 24c, d) seem to show the highest
selectivity between AI‐1 and AI‐2 inhibition.
As for Part A, the aryl ring of the structure seems to be an important component for activities be‐
cause the replacement of the aryl ring by an alkyl group led to a significant decrease in the activity. This
becomes very clear when the IC50 values of compounds with an alkyl chain at the Part A position such as
23k (Table 1.2, ester, >400 µM) and 24g (Table 1.2, thioester, 122 µM) are compared with most of the
other ethyl esters (around 150 µM for esters and 30 µM for thioesters). A heterocycle, such as the thio‐
phenyl group, is slightly better than a phenyl group. For example the IC50 values of compounds 23a/24a
(thiophenyl) are slightly lower than that of compounds 23b/24b (phenyl). Additional substituents on the
aryl ring seem to favor inhibition activities. For example, adding a bromo or a methoxyl group at the pa‐
ra‐ position of the phenyl ring resulted in significantly improved activities from an IC50 of 170 µM (23b)
to 17 µM (23g) and 87 µM (23j). However, if the substituent is on the meta‐ position, no improvement
was observed. A case in point is compound 23i, which has an IC50 of 163 µM.
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Table 1.3 Structures and activities of biaryl compounds
Compound

Ar =

X=

IC50 for AI‐2 (µM)

IC50 for AI‐1 (µM)

27a

Phenyl

O

8.7±2.9

293±108

28a

Phenyl

S

5.7±0.8

32±2

27b

4‐Methylphenyl

O

8.2±2.3

66±32

28b

4‐Methylphenyl

S

5.6±1.3

>400

27c

H2N

O

31±2

>200

27d

O

158±43

>400

27e

O

>400

>400

O

Because of the promising results with para‐substituted phenyl group in part A, we synthesized
additional compounds with a bulky substituent at the para‐position (Table 1.3). Several points are readi‐
ly noticeable in this series of compounds. First, the “biaryl” compounds tend to be more active than the
single aryl compounds unless the second aryl group has ring heteroatom and/or a substitution. For ex‐
ample, biaryl compounds 27a, b (8.2‐8.7 µM) and 28a, b (5.6‐5.7 µM) all have IC50 values in the single
digit micromolar range, while their corresponding “single aryl ring” analogs compounds 23b (170 µM)
and 24b (33 µM) have much lower activities. However, with an isoquinolinyl (27c) or dihydrobenzodioxi‐
nyl (27d) group as the second ring, the IC50 values are over 150 µM. Second, a methyl group on the addi‐
tional phenyl ring does not seem to make much difference. However, when a bulky group is attached,
the molecule starts to lose its activity. This point is demonstrated by the activity change from 27a to 27e,
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which has a quinoline as the second ring. Third, as for the selectivity in inhibition against AI‐2 and AI‐1, a
phenyl group extended by a second phenyl ring seems to improve the selectivity in biaryl compound 27a
(about 34 fold), whereas a polar substituent on the phenyl ring seems to decrease the selectivity for AI‐2
(e.g., 23g‐j and 24e‐f). Fourth, the effect of “thiation” of the carbonyl group in the biaryl series seems to
be less significant compared to those with only one aryl group. For example, the IC50 of biaryl com‐
pounds 27a‐b (esters, 8.2‐8.7 µM) are close to those of compounds 28a‐b (thioesters, about 5.6‐5.7 µM).
Overall, the introduction of a second aryl ring is advantageous for improved activity and selectivity.
The results of inhibition evaluation also revealed that reducing the sulfone group to a sulfoxide
seems to result in diminished activities. For example, compound 23g (sulfone) has an IC50 of 17 µM,
while the corresponding sulfoxide (26a, Table 1.4) has an IC50 of 48 µM. The possible reason for the ac‐
tivity difference may be due to the better structure mimicry of the borate group in AI‐2 by a sulfone
group than a sulfoxide. Additionally, a charged or polar terminal group (part D) also results in significant‐
ly reduced activities (25a, b, 32a, b, 38a, b)

Table 1.4 Structures and activities of other compounds
Compound

Structure

IC50 for AI‐2 (µM)

IC50 for AI‐1 (µM)

26a

48±14

303±10

25a

>400

>400

25b

>400

>400

32a

>400

>400

32b

150±30

>400
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38a

>400

Agonist

38b

267±49

‐‐

In order to exclude potentially misleading results caused by possible cytotoxicity, the effect of se‐
lected synthesized active inhibitors with IC50 values below 150 µM (21c, 21d, 23a, 24a, 24b, 23c, 24c,
23d, 24d, 23g, 24e, 23h, 23j, 24f, 27a, 28a, 27b, 28b, 27c, and 26a,) on bacterial growth was tested on
the MM32 strain of V. harveyi by following procedures published earlier.14 The results showed that none
of these compounds has cytotoxicity at concentrations, which are twice the IC50 value. That means the
decrease of bioluminescence production observed was solely due to the inhibition of quorum sensing.
To further explore the influence of the compounds on the growth of bacteria and to normalize
the bioluminescence to cell density, especially during the same time point in which we assayed for the
inhibition of fluorescence, a plate counting test was performed for the following compounds: KM‐03009,
27a, 27b, 27c, 28a and 28b, using the MM32 strain of V. harveyi. The bacteria culture incubated for 5
hours in the presence of a compound at a concentration, which was close to its IC50 was diluted to 1:100
and 1:1000, and plated onto fresh LM plates and incubated at 30 °C for 24‐48 hr. The colonies appeared
were counted and compared to the blank (bacteria incubated without any inhibitor). The number of CFU
(colony forming unit) of the bacteria incubated in the presence of an inhibitor at about the IC50 concen‐
tration was about the same as that of the blank. For example, the number of colonies appeared in the
presence of the inhibitors ranged from 80‐170% of that of the controls (without any inhibitors), while
the bioluminescence intensity of these experiments with inhibitors at IC50 concentrations was only 30‐60%
of the controls. Such results further suggested that the compounds indeed inhibited the luminescence
production (quorum sensing), not bacteria growth.
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1.2.3

Structure‐activity relationship of synthetic inhibitors
Aimed at achieving further understanding of the structure‐activity relationship, we also conduct‐

ed a Comparative Molecular Field Analysis (CoMFA). The CoMFA methodology is a 3D Quantitative
Structure‐Activity Relationship (3D‐QSAR) technique by analyzing the steric and electrostatic fields.15 In
this case all compounds were optimized by the semi‐empirical MOPAC/AM1 method16 and then as‐
signed with AM1BCC charges.17‐19 These conformations were then aligned with compound 28a (the most
potent compound) for CoMFA computation as depicted in Figure 1.5.

Figure 1.5 Molecular alignments of all compounds

CoMFA results suggest that the steric and electrostatic fields contribute 56% and 44% to AI‐2 in‐
hibitory activities, respectively. Statistically, the resulting standard error (SE) of 0.207, noncross‐
validated correlation coefficient (r2) of 0.931, cross‐validated coefficient (q2) of 0.922 and F value of
76.72 confirm the reliability of our CoMFA model. Table 1.5 shows that comparison of the calculated
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pIC50 and experimentally determined pIC50 values using the CoMSIA model developed and Figure 1.6
shows the schematic correlation of such data.

Table 1.5 Experimental pIC50, predicted pIC50 and residual values of molecules
used for CoMFA computation
Compound
Experimental pIC50 Predicted pIC50 Residual
KM‐03009

4.46

3.87

0.59

SPB‐02229

4.26

4.44

‐0.18

20a

3.00

3.22

‐0.22

20b

3.00

3.25

‐0.25

21b

4.05

3.87

0.18

20c

3.00

3.13

‐0.13

21c

3.86

3.91

‐0.05

20d

3.00

3.30

‐0.30

21d

4.04

3.71

0.33

23a

3.91

3.91

0.00

24a

4.66

4.32

0.33

23b

3.77

3.62

0.15

24b

4.48

4.55

‐0.07

23c

3.90

4.11

‐0.21

24c

4.47

4.38

0.09

23d

4.42

4.32

0.10

24d

4.48

4.56

‐0.08

23e

3.00

3.01

‐0.01

23f

3.00

3.12

‐0.12
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23g

4.77

4.51

0.26

24e

4.85

4.94

‐0.08

23h

4.09

3.76

0.34

23i

3.79

3.83

‐0.04

23j

4.06

4.13

‐0.07

24f

4.59

4.73

‐0.14

23k

3.00

3.04

‐0.04

24g

3.91

4.00

‐0.09

27a

5.05

4.89

0.15

28a

5.22

5.51

‐0.28

27b

5.10

4.95

0.15

28b

5.22

5.48

‐0.26

27c

4.51

4.40

0.11

27d

3.80

3.67

0.14

27e

3.00

2.97

0.03

26a

4.32

4.40

‐0.08

25a

3.00

3.10

‐0.10

25b

3.00

2.95

0.05

32a

3.00

3.08

‐0.08

32b

3.82

3.85

‐0.03

38a

3.00

3.01

‐0.01

38b

3.57

3.69

‐0.11

22

6.0

5.5

Predicted pIC50

5.0

4.5

4.0

3.5

3.0

2.5
2.5

3.0

3.5

4.0

4.5

5.0

5.5

6.0

Experimental pIC50

Figure 1.6 Experimental versus predicted pIC50 for CoMFA 3D‐QSAR model

For clarity in presentation, two 3D contour maps are shown in Figure 1.7. In the steric contour
map, a high density of green and yellow colors around the R1 substituent (Figure 1.4) suggests that a
moderate bulky aromatic ring, such as diphenyl ring, is favorable; in the meanwhile the yellow color
around the R2 substituent also indicates a less bulky group here is desired. In the electrostatic contour
map, a red color around the sulfonyl moiety and the R2 substituent suggests that the less electronega‐
tive substituents in these positions could enhance the biological activity. The CoMFA model may provide
useful insight into the future design of novel AI‐2 inhibitors.

Figure 1.7 3D contour maps around compound 28a as the result of a CoMFA analysis of the AI‐2 inhibi‐
tory activities.
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Regions where substitution enhances (green) or reduces (yellow) the inhibitory affinity (left); the
color coding indicates regions where electronegative substituents would enhance (blue) or reduce (red)
the inhibitory activities (right).

Though the studies presented give an initial understanding of the structure‐activity relationship,
it should be noted that whole cell bacterial assays have certain intrinsic experimental variations that
may not allow us to draw firm conclusions related to structural variations that only resulted in small
changes in activities. When the same compound was tested using an entirely new batch of bacteria from
the same source, IC50 variations of up to 1‐3 fold were observed in some extreme cases. Though such
variations are common in whole cell bacterial assay, one does need to be careful in drawing quantitative
conclusions. The results presented can be viewed as a qualitative trend.
1.3

Experimental section
General information
All reagents were purchased from Acros and Aldrich. Boronic acids were provided by Frontier

Scientific, Inc. DPD was synthesized following literature procedures.20, 21 1H‐NMR and 13C‐NMR spectra
were recorded at 400 and 100 MHz, respectively, on a Bruker 400 NMR spectrometer. Mass spectral
analyses were performed by the mass spectrometry facilities at Georgia State University.
1.3.1

Synthesis and characterization of small molecule analogues
General Experimental Procedure for Substitution Reaction of Thiol and Haloacetamides, Halo‐

acetates or 5‐(Bromomethyl)isoxazole. Representative Procedure for Substitution of Thiophene‐2‐
thiol (18a) and 2‐Iodoacetamide (Schemes 1.2 and 1.3, reaction a; Scheme 1.5, reaction b): A mixture
of thiophene‐2‐thiol (18a, 690 mg, 5.94 mmol, 2.2 equiv.), 2‐iodoacetamide (499 mg, 2.7 mmol, 1.0
equiv.) and potassium carbonate (560 mg, 4.05 mmol, 1.5 equiv.) in acetone (20 mL) was heated under
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reflux for 6 h (TLC). The solution was filtered and solvent was evaporated. Dichloromethane (50 mL) was
added to dissolve the residue. The solution was washed with saturated NaHCO3 (8 mL × 2), H2O (5 mL × 2)
and brine (10 mL), and dried over Na2SO4. Evaporation of solvent afforded the crude product which was
purified by column chromatography (Hex/EtOAc, 2:1) to give 2‐(thiophen‐2‐ylthio)acetamide (19a, 229
mg, 49%) as light yellow oil. The crude product can also be used in the next step without purification.

Ethyl 2‐(phenylthio)acetate (22b). Yellow oil; yield 64%; 1H NMR (CD3OD) δ 7.39‐7.40 (d, J = 7.2
Hz, 2H), 7.28‐7.31 (t, J = 7.2 Hz, 7.68 Hz, 2H), 7.20‐7.24 (t, J = 6.8 Hz, 7.6 Hz, 1H), 4.08‐4.13 (t, J = 7.2 Hz,
2H), 3.68 (s, 2H), 1.16‐1.19 (t, J = 7.2 Hz, 3H); GC‐MS, m/z 196 (M+).

Ethyl 2‐(4‐bromophenylthio)acetate (22g). Colorless oil; yield 87%; 1H NMR (CDCl3) δ 7.41‐7.43
(d, J = 8.4, 2H), 7.26‐7.30 (d, J = 8.4 Hz, 2H) , 4.14‐4.19 (q, J = 7.2 Hz, 2H), 3.61 (s, 2H), 1.21‐1.25 (t, J = 7.2
Hz, 3H); 13C NMR (CDCl3) δ 169.4, 134.2, 132.1, 131.5, 121.0, 61.7, 36.6, 14.1; MS (ES+), m/z 275.0 (M+1)
+

.

Methyl 2‐(4‐bromophenylthio)acetate (22h). Colorless oil; yield 56%; 1H NMR (CDCl3) δ 7.42‐
7.44 (d, J = 8.4 Hz, 1H), 7.26‐7.29 (d, J = 8.8 Hz, 1H), 3.72 (s, 3H), 3.63 (s, 2H), 13C NMR (CDCl3) δ 169.9,
134.1, 132.1, 131.5, 121.1, 52.6, 36.4; MS (ES+), m/z 282.9 (M+23) +.

Ethyl 2‐(4‐methoxyphenylthio)acetate (22j). Colorless oil; yield 99%; 1H NMR (CDCl3) δ 7.41‐
7.43 (d, J = 8.8 Hz, 2H), 6.83‐6.86 (d, J = 8.8 Hz, 2H) , 4.11‐4.17 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 3.51 (s, 2H),
1.20‐1.23 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 169.9, 159.6, 134.2, 124.9, 114.6, 61.3, 55.3, 38.6, 14.1;
MS (ES+), m/z 227.1 (M+1) +.
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Ethyl 2‐(propylthio)acetate (22k). Colorless oil; yield 77%; 1H NMR (CDCl3) δ 4.17‐4.22 (q, J = 7.2
Hz, 2H), 3.21 (s, 2H), 2.60‐2.64 (t, J = 14.8 Hz, 2H) , 1.59‐1.68 (m, J = 7.2 Hz, 2H), 1.27‐1.31 (t, J = 7.2 Hz,
3H), 0.98‐1.01 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 170.6, 61.2, 34.6, 33.6, 22.3, 14.1, 13.3; MS (ES+), m/z
163.1 (M+1) +.

5‐(Phenylthiomethyl)isoxazole (31b). Yellow oil; yield 87%; 1H NMR (CDCl3) δ 8.15 (s, 1H), 7.25‐
7.38 (m, 5H), 6.07 (s, 1H), 4.19 (s, 2H); GC‐MS, m/z, 191 (M+).

General Experimental Procedure for Oxone Oxidation Reaction. Representative Procedure for
Oxidation of 2‐(Thiophen‐2‐ylthio)acetamide (19a) (Schemes 1.2 and 1.3, reaction b; Scheme 1.5, reac‐
tion c, Scheme 1.6, reaction d): To a stirred solution of 2‐(thiophen‐2‐ylthio)acetamide (19a, 229 mg,
1.32 mmol, 1.0 equiv.) in MeOH (5.4 mL) and THF (5.4 mL) was added the solution of oxone (1.12 g, 1.82
mmol, 1.38 equiv.) in H2O (7.2 mL) dropwise. The mixture was stirred at room temperature overnight.
The solution was filtered and solvent was removed. Then dichloromethane (50 mL) was added and the
solution was washed with H2O (8 mL), brine (8 mL × 2), and dried over Na2SO4. Evaporation of solvent
afforded the crude product which was purified by column chromatography (Hex/EtOAc 2:1 – 1:1) to give
2‐(thiophen‐2‐ylsulfonyl)acetamide (20a, 241 mg, 89%) as white solid.

2‐(Thiophen‐2‐ylsulfonyl)acetamide (20a). White solid; yield 44% for two steps; 1H NMR
(CD3OD): δ 7.97 (s, 1H), 7.78 (s, 1H), 7.23‐7.24 (d, 1H), 4.23 (s, 2H); 13C NMR (CD3OD): δ 164.4, 139.5,
135.0, 127.7, 62.4; MS (ES+), m/z 206 (M+1) +, 228 (M+Na)+.
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2‐(Phenylsulfonyl)acetamide (20b). White solid; yield 89% in two steps. 1H NMR ((CD3)2CO) δ
7.95‐7.97 (m, 2H), 7.73‐7.77 (m, 1H), 7.63‐7.67 (m, 2H), 6.71‐7.18 (br, 2H), 4.17 (s, 2H);
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C NMR

((CD3)2CO) δ 162.4, 139.9, 133.8, 129.1, 128.3, 61.4; MS (ES+), m/z 200 (M+1) +, 222 (M+Na)+.

N,N‐Diethyl‐2‐(thiophen‐2‐ylsulfonyl)acetamide (20c).Light yellow crystals; yield 78% in 2 steps;
1

H NMR (CDCl3) δ 7.74‐7.76 (m, J = 4.8 Hz, 2H), 7.15‐7.18 (t, J = 4.8 Hz, 1H), 4.29 (s, 2H), 3.45‐3.50 (q, J =

7.2 Hz, 2H), 3.34‐3.40 (q, J = 7.2 Hz, 2H), 1.20‐1.24 (t, J = 7.2 Hz, 3H), 1.11‐1.14 (t, J = 7.2 Hz, 3H), 13C
NMR (CDCl3) δ 160.6, 139.6, 135.6, 135.0, 128.0, 61.0, 43.3, 41.1,14.4, 13.0; MS (ES‐), m/z 260.0 (M‐1) ‐,
m.p. = 89‐90 °C.

N,N‐Diethyl‐2‐(phenylsulfonyl)acetamide (20d). White crystals 72% for 2 steps; 1H NMR (CDCl3)
δ 7.92‐7.94 (d, J = 7.2 Hz, 2H), 7.65‐7.69 (t, J = 7.2 Hz, 1H), 7.55‐7.59 (t, J = 7.6 Hz, 2H), 4.21 (s, 2H), 3.45‐
3.51 (q, J = 7.2 Hz, 2H), 3.32‐3.37 (q, J = 7.2 Hz, 2H), 1.20‐1.24 (t, J = 7.2 Hz, 3H), 1.08‐1.11 (t, J = 7.2 Hz,
3H), 13C NMR (CDCl3) δ 160.6, 139.0, 134.3, 129.2, 128.8, 60.0, 43.3, 41.0,14.4, 12.9; MS (ES‐), m/z 255.0
(M‐1)‐; m.p. = 84‐85 °C.

Ethyl 2‐(thiophen‐2‐ylsulfonyl)acetate (23a). colorless oil; yield 71% in two steps; 1H NMR
(CDCl3) δ 7.80‐7.81 (dd, J = 1.2 Hz, 3.6 Hz, 4.8 Hz, 1H), 7.76‐7.78 (dd, J = 1.2 Hz, 4.0 Hz, 4.8 Hz, 1H), 7.18‐
7.20 (q, J = 1.2 Hz, 3.6 Hz, 4.0 Hz, 1H), 4.22 (s, 1H), 4.16‐4.21 (q, J = 7.2 Hz, 2 H), 1.21‐1.25 (t, J = 7.2 Hz, 3
H); 13C NMR (CDCl3) δ 162.3, 139.3, 135.4, 135.1, 128.0, 62. 5, 62.0, 13.9; MS (ES+), m/z, 235 (M+), 257
(M+Na)+.

Ethyl 2‐(phenylsulfonyl)acetate (23b). White solid; yield 71%; 1H NMR (CDCl3) δ 7.95‐7.97 (d, J =
7.6 Hz, 2H), 7.68 – 7.72 (t, J = 7.2 Hz, 1H), 7.57‐7.61 (t, J = 7.2 Hz, 7.6 Hz, 2H),4.17 (s, 1H), 4.12‐4.15 (q, J =
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7.2 Hz, 2H), 1.17–1.26 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.3, 138.7, 134.3, 129.2, 128.6, 62.4, 61.0,
13.9; MS (ES+), m/z, 229 (M+1) +, 251 (M+Na)+; m.p. = 43‐44 °C.

Isopropyl 2‐(thiophen‐2‐ylsulfonyl)acetate (23c). Colorless oil, yield 95% in two steps; 1H NMR
(CDCl3) δ 7.69‐7.71 (m, 2H), 7.10 – 7.12 (t, J = 4.0 Hz, 1H), 4.94‐ 4.97 (m, J = 6.0 Hz, 1H) 4.11 (s, 2H), 4.15
– 4.20 (d, J = 6.0 Hz, 6H). 13C NMR (CDCl3) δ 161.7, 139.4, 135.3, 134.8, 127.8, 70.6, 62.3, 21.5; MS (ES‐),
m/z, 247 (M‐1) ‐

Isopropyl 2‐(phenylsulfonyl)acetate (23d). Colorless oil; yield 92% in two steps; 1H NMR (CDCl3)
δ 7.92‐7.94 (d, J = 8.0 Hz, 2H), 7.64 – 7.68 (m, 1H), 7.54‐7.58 (m, 2H), 4.91‐ 4.97 (m, J = 6.0 Hz, 1H) 4.07
(s, 2H), 4.13, 4.14 (d, J = 6.0 Hz, 6H). 13C NMR (CDCl3) δ 161.8, 138.8, 134.2, 129.1, 128.5, 70.4, 61.2, 21.4;
MS (ES‐), m/z 241 (M‐1)‐.

Methyl 2‐(thiophen‐2‐ylsulfonyl)acetate (23e). Colorless oil; yield 73% in two steps; 1H NMR
(CDCl3) δ 7.76‐7.68 (m, 2H), 7.17‐7.19 (t, J = 4.4 Hz, 1H), 4.21 (s, 1H), 3.75 (s, 3H); MS (ES+), m/z 221
(M+1)+, 243 (M+Na) +.

Methyl 2‐(phenylsulfonyl)acetate (23f). Colorless oil; yield 80% in two steps; 1H NMR (CDCl3) δ
7.88‐7.90 (d, J = 8.0 Hz, 2H), 7.62 – 7.66 (t, J = 7.2 Hz, 1H), 7.51‐7.55 (m, J = 7.2 Hz, 8.0 Hz, 2H), 4.07 (s,
1H), 3.64 (s, 3H); MS (ES‐), m/z 213 (M‐1)‐.

Ethyl 2‐(4‐bromophenylsulfonyl)acetate (23g). Colorless crystal, yield 90%; 1H NMR (CDCl3) δ
7.81‐7.83 (d, J = 8.8 Hz, 2H), 7.72‐7.74 (d, J = 8.4 Hz, 2H) , 4.14‐4.19 (q, J = 7.2 Hz, 2H), 4.11 (s, 2H), 1.21‐
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1.24 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.2, 137.6, 132.5, 130.2, 129.8, 62.5, 60.9, 13.9; MS (ES+),
m/z 328.9 (M+23) +; m.p. = 49‐50 °C.

Methyl 2‐(4‐bromophenylsulfonyl)acetate (23h). White crystals; yield 88%; 1H NMR (CDCl3) δ
7.81‐7.83 (d, J = 8.8 Hz, 2H), 7.72‐7.75 (d, J = 8.8 Hz, 2H) , 4.13 (s, 2H), 3.73 (s, 3H); 13C NMR (CDCl3) δ
162.7, 137.6, 132.6, 130.1, 129.9, 60.6, 53.2; MS (ES+), m/z 314.9 (M+23) +; m.p. = 78‐79 °C.

Ethyl 2‐(3‐bromophenylsulfonyl)acetate (23i). Colorless crystals; yield 75% in two steps; 1H
NMR (CDCl3) δ 8.11 (s, 1H), 7.90‐7.92 (d, J = 7.9 Hz, 1H), 7.82‐7.84 (d, J = 7.9 Hz, 1H), 7.47‐7.51 (t, J = 7.9
Hz, 1H), 4.15‐4.21 (q, J = 7.1 Hz, 2H), 4.15 (s, 2H); 13C NMR (CDCl3) δ 162.0, 140.4, 137.3, 131.5, 130.7,
127.2, 123.1, 62.5, 60.9, 13.8; MS (ES+), m/z 329.1 (M+23) +; m.p. = 36‐37 °C.

Ethyl 2‐(4‐methoxyphenylsulfonyl)acetate (23j). Colorless oil; yield 71%; 1H NMR (CDCl3) δ 7.86‐
7.88 (d, J = 8.8 Hz, 2H), 7.02‐7.04 (d, J = 9.2 Hz, 2H) , 4.13‐4.18 (q, J = 6.8 Hz, 2H), 4.09 (s, 2H), 3.89 (s, 3H),
1.20‐1.24 (t, J = 6.8 Hz, 3H); 13C NMR (CDCl3) δ 164.2, 162.6, 130.8, 130.2, 114.3, 62.3, 61.2, 55.7, 13.9;
MS (ES+), m/z 281.0 (M+23) +.

Ethyl 2‐(propylsulfonyl)acetate (23k). Colorless oil; yield 84%; 1H NMR (CDCl3) δ 4.25‐4.31 (q, J =
7.2, 2H), 3.95 (s, 2H), 3.22‐3.26 (m, J = 8.0 Hz, J = 2.4, 2H) , 1.90‐1.95 (m, J = 7.6 Hz, J = 2.4 Hz, 2H), 1.31‐
1.35 (t, J = 7.2 Hz, 3H), 1.10‐1.13 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 163.1, 62.6, 57.4, 55.2, 15.7, 13.9,
13.0; MS (ES+), m/z 317.0 (M+23) +.

5‐((Thiophen‐2‐ylsulfonyl)methyl)isoxazole (32a). Yellow solid, yield 69% in two steps; 1H NMR
(CDCl3) δ 8.25‐8.26 (d, 1H), 7.53‐7.77 (dd, J = 1.2 Hz, 1.6 Hz, 5.2 Hz, 1H), 7.57‐7.58 (dd, J = 1.6 Hz, 4.0 Hz),
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7.13‐7.16 (q, J = 4.0 Hz, 5.2 Hz, 1H), 7.45‐7.46 (d, 1H), 4.69 (s, 2H); 13C NMR (CDCl3) δ 159.7, 150.7, 137.9,
135.6, 135.4, 128.2, 105.6, 55.0; MS (ES+), m/z 230 (M+1) +.

5‐(Phenylsulfonylmethyl)isoxazole (32b). Yellow solid, yield 62%; 1H NMR (CDCl3) δ 8.22 (s, 1H),
7.77‐7.79 (d, J = 8.0 Hz, 2H), 7.66‐7.70 (t, J = 7.2 Hz, 2H), 7.26‐7.56 (t, J = 7.6 Hz, 2H), 6.38 (s, 1H), 4.60 (s,
2H); 3C NMR (CDCl3) δ 159.7, 150.6, 137.6, 134.6, 129.4, 128.4, 105.4, 53.8; MS (ES+), m/z 224 (M+1) +,
246(M+Na)+, m.p. = 87‐88 °C.

2‐(Phenylsulfonyl)acetaldehyde oxime (37b). White solid; yield 84%; 1H NMR ((CD3)2CO,
mixture of isomers, ratio 1/1) δ 10.69 (s, 0.5H), 10.49 (s, 0.5 H), 7.66‐7.98 (m, 5H), 7.33 (t, 0.5H), 6.82 (t,
0.5H), 4.37 (d, 1H), 4.11(d, 1H); MS (ES+), m/z 200 (M+1) +, 222(M+Na)+; m.p. = 91‐94 °C.

General Experimental Procedure for Thiation Reaction of Amides. Representative Procedure
for Thiation of 2‐(Phenylsulfonyl)acetamide (20a) (Scheme 1.2, reaction c): To a solution of 2‐
(thiophen‐2‐ylsulfonyl)acetamide (20a, 33 mg, 0.17 mmol, 1.0 equiv.) in anhydrous THF (5 mL) was
added Lawesson’s reagent (67 mg, 0.17 mmol, 1.0 equiv.) at room temperature under N2; then the
reaction was heated at reflux for 2 h. After solvent was evaporated, the residue was dissolved in
dichloromethane (50 mL). The solution was washed with H2O (5 mL), brine (5 mL), and dried over Na2SO4.
Evaporation of solvent afforded the crude product which was purified by column chromatography
(Hex/EtOAc/Acetone 1:1:0.01) to give 2‐(Phenylsulfonyl)ethanethioamide (KM‐03009, 22 mg, 61%) as
white solid.

2‐(Thiophen‐2‐ylsulfonyl)ethanethioamide (KM‐03009). White solid, yield 38%;

1

H NMR

((CD3)2CO) δ 9.13 (br, 1H), 8.70 (br, 1H), 8.05‐8.06 (dd, J = 1.2 Hz, 4.8 Hz, 1H), 7.77‐7.79 (dd, J = 1.2 Hz,
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4.0 Hz), 7.26‐7.28 (dd, J = 4.0 Hz, 4.8 Hz, 1H), 4.66 (s, 2H); 13C NMR ((CD3)2CO) δ 192.7, 139.0, 135.5,
135.2, 127.9, 70.5; MS (ES+), m/z 222 (M+1) +, 244 (M+Na)+; m.p. = 154‐155 °C.

2‐(Phenylsulfonyl)ethanethioamide (21b). White solid; yield 61%; 1H NMR ((CD3)2CO) δ 8.61‐
9.12 (br, 2H), 7.94‐7.96 (m, 2H), 7.74‐7.78 (m, 1H), 7.63‐7.67 (m, 2H), 4.60 (s, 2H); 13C NMR ((CD3)2CO) δ
192.9, 138.6, 134.1, 129.0, 128.7, 69.1; MS (ES+), m/z 216 (M+1) +, 238 (M+Na)+, m.p. = 165‐166 °C.

N,N‐Diethyl‐2‐(thiophen‐2‐ylsulfonyl)ethanethioamide (21c). Light yellow solid; yield 25%; 1H
NMR (CDCl3) δ 7.76‐7.77 (d, J = 5.0 Hz, 1H), 7.69‐7.71 (d, J = 3.8 Hz, 1H), 7.16‐7.18 (m, J = 3.8 Hz, J = 5.0
Hz, 1H), 4.80 (s, 2H), 3.92‐3.97 (q, J = 7.2 Hz, 2H), 3.84‐3.89 (q, J = 7.2 Hz, 2H), 1.29‐1.32 (t, J = 7.2 Hz, 3H),
1.25‐1.29 (t, J = 7.2 Hz, 3H), 13C NMR (CDCl3) δ 185.0, 138.2, 136.1, 134.9, 127.7, 69.3, 48.2, 47.6, 13.3,
10.8; MS (ES+), m/z 278.2 (M+1) +, m.p. = 98‐99 °C.

N,N‐Diethyl‐2‐(phenylsulfonyl)ethanethioamide (21d). White solid, yield 30%,; 1H NMR (CDCl3)
δ 7.88‐7.90 (d, J = 7.2 Hz, 2H), 7.66‐7.70 (t, J = 7.4 Hz, 1H), 7.54‐7.58 (t, J = 8.0 Hz, 2H), 4.73 (s, 2H), 3.91‐
3.96 (q, J = 7.2 Hz, 2H), 3.86‐3.90 (q, J = 7.2 Hz, 2H), 1.31‐1.33 (t, J = 7.2 Hz, 3H), 1.25‐1.28 (t, J = 7.2 Hz,
3H), 13C NMR (CDCl3) δ 185.2, 137.8, 134.2, 129.2, 128.8, 68.4, 48.1, 47.6, 13.3, 10.8; MS (ES+), m/z 272.2
(M+1) +, m.p. = 103‐105 °C.

General Experimental Procedure for Thiation Reaction of Esters. Representative Procedure for
Thiation of Ethyl 2‐(Thiophen‐2‐ylsulfonyl)acetate (23a) (Scheme 1.3, reaction c; Scheme 1.4, reaction
b): To a solution of ethyl 2‐(thiophen‐2‐ylsulfonyl)acetate (23a, 50 mg, 0.22 mmol, 1.0 equiv.) in
anhydrous o‐xylene (2 mL) was added Lawesson’s reagent (174 mg, 0.43 mmol, 2.0 equiv.) under N2. The
reaction was heated under reflux for 6 h. After solvent was evaporated, the residue was dissolved in
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dichloromethane (50 mL) and the solution was washed with H2O (5 mL), brine (5 mL × 2), and dried over
Na2SO4. Evaporation of solvent afforded the crude product, which was purified by column
chromatography (Hex/EtOAc, 6:1) to give O‐ethyl 2‐(thiophen‐2‐ylsulfonyl)ethanethioate (24a, 18 mg,
34%) as light yellow solid.

O‐Ethyl 2‐(thiophen‐2‐ylsulfonyl)ethanethioate (24a). Light yellow solid; yield 34%; 1H NMR
((CD3)2CO) δ 8.10 (s, 1H), 7.78 (s, 1H), 7.31 (d, 1H), 4.79 (s, 2H), 4.43‐4.45 (d, J = 6.8 Hz, 2H), 1.27‐1.30 (t,
J = 6.8 Hz, 3H); 13C NMR ((CD3)2CO) δ 206.1, 139.4, 135.5, 135.4, 128.1, 72.3, 69.6, 12.7; MS (ES+), m/z
251 (M+1) +, 268 (M+H2O)+, 273 (M+Na)+; m.p. = 50‐51 °C.

O‐Ethyl 2‐(phenylsulfonyl)ethanethioate (24b). White solid; yield 31%; 1H NMR ((CD3)2CO) δ
7.92‐7.94 (m, 2H), 7.77‐7.91 (m, 1H), 7.66‐7.70 (m, 2H), 4.72 (s, 2H), 4.35‐3.38 (q, J = 7.2 Hz, 2H), 1.18‐
1.22 (t, J = 7.2 Hz, 3H); 13C NMR ((CD3)2CO) δ 206.4, 139.0, 134.1, 129.1, 128.6, 71.1, 69.4, 12.5; MS (ES+),
m/z, 245 (M+1) +, 267 (M+Na)+; m.p. = 33‐34 °C.

O‐Isopropyl 2‐(thiophen‐2‐ylsulfonyl)ethanethioate (24c). Yellow solid; yield 24%; 1H NMR
((CD3)2CO) δ 8.07 – 8.09 (m, 1H), 7.77‐7.78 (m, 1H), 7.31 – 7.29 (m, 1H), 5.47‐ 5.50 (m, J = 6.0 Hz, 1H)
4.75 (s, 2H), 1.27,1.29 (d, J = 6.0 Hz, 6H); 13C NMR ((CD3)2CO) δ 206.7, 141.0, 136.9, 136.7, 129.5, 78.5,
74.1, 21.4; MS (ES+), m/z 287 (M+Na) +; m.p. = 53‐55 °C.

O‐Isopropyl 2‐(phenylsulfonyl)ethanethioate (24d). Yellow solid; yield 27%; 1H NMR ((CD3)2CO)
δ 7.93, 7.95 (d, J = 7.6 Hz, 2H), 7.77‐7.79 (d, J = 7.2 Hz, 1H), 7.66‐7.70 (t, J = 7.6 Hz, 8.0 Hz, 2H), 5.41‐ 5.43
(m, J = 6.4 Hz, 1H) 4.70 (s, 2H), 1.19‐1.21 (d, J = 6.4 Hz, 6H); 13C NMR ((CD3)2CO) δ 206.9, 140.5, 135.4,
130.6, 130.0, 78.3, 72.8, 21.3; MS (ES‐), m/z 257 (M‐1)‐ ; m.p. = 36‐37 °C.
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O‐Ethyl 2‐(4‐bromophenylsulfonyl)ethanethioate (24e). Light yellow solid; yield 20%; 1H NMR
(CDCl3) δ 7.74‐7.76 (d, J = 8.8 Hz, 2H), 7.70‐7.72 (d, J = 8.8 Hz, 2H) , 4.52 (s, 2H), 4.40‐4.45 (q, J = 7.2 Hz,
2H), 1.29‐1.33 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 204.3, 137.0, 132.4, 130.3, 129.6, 71.4, 69.7, 13.3;
MS (ES+), m/z 344.9 (M+23) +; m.p. = 84‐85 °C.

O‐Ethyl 2‐(4‐methoxyphenylsulfonyl)ethanethioate (24f). Light yellow solid; yield 18%; 1H NMR
(CDCl3) δ 7.80‐7.82 (d, J = 9.2 Hz, 2H), 7.00‐7.02 (d, J = 9.2 Hz, 2H) , 4.51 (s, 2H), 4.40‐4.45 (q, J = 7.2 Hz,
2H), 3.90 (s, 3H), 1.29‐1.33 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 205.1, 164.1, 131.0, 129.7, 114.2, 71.8,
69.5, 55.7, 13.3; MS (ES+), m/z 297.0 (M+23) +; m.p. = 58‐59 °C.

O‐Ethyl 2‐(propylsulfonyl)ethanethioate (24g). Light yellow oil; yield 9.4%; 1H NMR (CDCl3) δ
4.56‐4.62 (q, J = 7.2, 2H), 4.37 (s, 2H), 3.21‐3.25 (m, J = 7.9 Hz, J = 2.4 Hz, 2H) , 1.91‐1.97 (m, J = 7.6 Hz, J
= 2.0 Hz, 2H), 1.44‐1.48 (t, J = 7.2 Hz, 3H), 1.09‐1.12 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 205.7, 69.9,
68.1, 54.4, 29.7, 16.0, 13.4, 13.0; MS (ES+), m/z 233.0 (M+23) +.

Compound 28a. Light yellow solid; yield 17%; 1H NMR (CDCl3) δ 7.93‐7.95 (d, J = 8.6 Hz, 2H),
7.73‐7.76 (d, J = 8.6 Hz, 2H), 7.59‐7.61 (d, J = 6.9 Hz, 2H), 7.46‐7.50 (t, J = 7.0 Hz, 2H), 7.42‐7.44 (t, J = 7.1
Hz, 1H), 4.55 (s, 2H), 4.41‐4.47 (q, J = 7.1 Hz, 2H), 1.27‐1.31 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3) δ 204.7,
147.1, 139.0, 136.6, 129.3, 129.1, 128.8, 127.6, 127.4, 71.6, 69.6, 13.3; MS (ES‐), m/z 319.0 (M‐1) ‐; m.p. =
70‐72 °C.

Compound 28b. White solid; yield 21%; 1H NMR (CDCl3) δ 7.92‐7.94 (d, J = 8.8 Hz, 2H), 7.74‐7.76
(d, J = 8.4 Hz, 2H), 7.52‐7.54 (d, J = 8.0 Hz, 2H), 7.29‐7.31 (d, J = 7.6 Hz, 2H), 4.56 (s, 2H), 4.41‐4.44 (q, J =
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7.2 Hz, 2H), 2.42 (s, 1H), 1.26‐1.29 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.4, 147.2, 138.9, 136.8, 136.0,
129.8, 129.1, 127.5, 127.2, 62.4, 61.1, 21.1, 13.9; MS (ES+), m/z 357.1 (M+23) +; m.p. = 98‐100 °C.

General Experimental Procedure for Cross Coupling Reaction. Representative Procedure for
Cross Coupling of Ethyl 2‐(4‐Bromophenylsulfonyl)acetate (23g) and Phenylboronic Acid (Scheme 1.4,
reaction a): A mixture of ethyl 2‐(4‐bromophenylsulfonyl)acetate (23g, 188.7 mg, 0.61 mmol, 1 equiv.),
phenylboronic acid (180 mg, 1.47 mmol, 2.4 equiv.), Pd(OAc)2 (11 mg, 0.049 mmol, 0.08 equiv.), PPh3 (39
mg, 0.147 mmol, 0.24 equiv.) and K2CO3 (255 mg, 1.84 mmol, 3.0 equiv.) in DMF (3.3 mL) was degassed
using vacuum pump and backfilled with N2. Then the reaction mixture was heated and stirred at 90 °C
overnight. After cooling to room temperature, the resulting mixture was poured into 5.0 mL 1N HCl (in
ice bath). Then the mixture was extracted with EtOAc (40 mL). The organic extract was washed with
brine (8 mL) and dried over Na2SO4. Evaporation of solvents and purification of the residue by column
chromatography (Hexanes:EtOAc 8:1 – 5:1) gave the pure compound (27a) as white solid (79 mg, 42%).

Compound 27a. White solid; 42%; 1H NMR (CDCl3) δ 8.00‐8.02 (d, J = 8.8 Hz, 2H), 7.76‐7.79 (d, J
= 8.4 Hz, 2H), 7.61‐7.63 (d, J = 6.8 Hz, 2H), 7.47‐7.51 (t, J = 6.8 Hz, 2H), 7.44‐7.46 (t, J = 7.2 Hz, 1H), 4.15‐
4.20 (q, J = 7.2 Hz, 2H), 4.15 (s, 2H), 1.20‐1.23 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.4, 147.2, 139.0,
137.2, 129.1, 128.8, 127.8, 127.4, 62.4, 61.1, 13.7; MS (ES+), m/z 327.2 (M+23) +, m.p. = 108‐110 °C.

Compound 27b. White solid; yield 49%; 1H NMR (CDCl3) δ 7.98‐7.80 (d, J = 8.8 Hz, 2H), 7.74‐7.77
(d, J = 8.4 Hz, 2H), 7.50‐7.53 (d, J = 8.0 Hz, 2H), 7.29‐7.31 (d, J = 8.0 Hz, 2H), 4.15‐4.19 (q, J = 7.2 Hz, 2H),
4.15 (s, 2H), 2.42 (s, 1H), 1.19‐1.23 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.4, 147.2, 138.9, 136.8, 136.0,
129.8, 129.1, 127.5, 127.2, 62.4, 61.1, 21.1, 13.9; MS (ES+), m/z 341.3 (M+23) +; m.p. = 83‐85 °C.

34
Compound 27c. White solid; yield 37%; 1H NMR ((CD3)2CO) δ 8.06‐8.11 (m, J = 8.4 Hz, J = 8.8 Hz,
4H), 8.01‐8.03 (d, J = 8.8 Hz, 2H), 7.86‐7.89 (d, J = 8.8 Hz, 2H), 4.42 (s, 2H), 4.10‐4.12 (q, J = 7.2 Hz, 2H),
1.12‐1.16 (t, J = 7.2 Hz, 3H);

13

C NMR (Acetone‐d6) δ 168.4, 163.5, 146.5, 142.6, 139.8, 135.5, 130.2,

129.3, 128.7, 128.3, 62.6, 61.5, 14.2; MS (ES+), m/z 370.2 (M+23) +; m.p. = 181‐183 °C.

Ethyl 2‐(4‐(2,3‐dihydrobenzo[b][1,4]dioxin‐6‐yl)phenylsulfonyl)acetate (27d). White solid; yield
88%; 1H NMR (CDCl3) δ 7.95‐7.97 (d, J = 8.8 Hz, 2H), 7.70‐7.72 (d, J = 8.4 Hz, 2H), 7.14‐7.15 (t, J = 2.4 Hz,
1H), 7.11‐7.13 (m, J = 8.4 Hz, J = 2.4 Hz, 1H), 6.96‐6.98 (d, J = 8.4 Hz, 1H) , 4.31 (s, 4H), 4.14 (s, 2H), 4.14‐
4.17 (q, J = 7.2 Hz, 2H), 1.19‐1.23 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.4, 146.6, 144.4, 143.9, 136.6,
132.3, 129.1, 127.2, 120.5, 117.9, 116.2, 64.5, 64.4, 62.4, 61.1, 13.9; MS (ES+), m/z 385.3 (M+23) +; m.p. =
116‐118 °C.

Ethyl 2‐(4‐(isoquinolin‐4‐yl)phenylsulfonyl)acetate (27e). Light yellow solid; yield 30%; 1H NMR
(CDCl3) δ 9.33 (s, 1H), 8.50 (s, 1H), 8.11‐8.14 (d, J = 8.4 Hz, 2H), 8.08‐8.11 (d, J = 7.6 Hz, 1H), 7.80‐7.82 (d,
J = 8.4 Hz, 1H), 7.73‐7.77 (m, J = 8.4 Hz, 2H), 7.67‐7.72 (t, J = 8.4 Hz, 2H) , 4.20‐4.25 (q, J = 7.2 Hz, 2H),
4.23 (s, 2H), 1.24‐1.28 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 162.4, 153.1, 143.5, 142.8, 138.3, 133.6,
131.2, 130.8, 128.9, 128.1, 127.7, 124.0, 62.5, 61.0, 13.9; MS (ES+), m/z 356.0 (M+1)+; m.p. = 123‐125 °C.

Experimental Procedure for m‐CPBA Oxidation of Ethyl 2‐(4‐Bromophenylthio)acetate (23g).
(Scheme 1.3, reaction v): A solution of m‐CPBA (110 mg, 75% pure, 0.48 mmol, 1 equiv.) in DCM (3.5 mL)
was added dropwise to a stirred solution of ethyl 2‐(4‐bromophenylthio)acetate (132 mg, 0.48 mmol, 1
equiv.) at 0 °C. Then the reaction mixture was stirred at 0 °C for 25 min. The reaction solution was
filtered and diluted with DCM (10 mL) and was washed with saturated NaHCO3 (8 mL × 2), H2O (8 mL)
and brine (10 mL). The organic layer was dried over Na2SO4. Then the solvent was removed under
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vacuum to give the crude product, which was purified by column chromatography (Hex/EtOAc 3:1) to
give pure ethyl 2‐(4‐bromophenylsulfinyl)acetate (26a, 119 mg, 85%) as colorless crystals.

Ethyl 2‐(4‐bromophenylsulfinyl)acetate (26a). Colorless crystals, yield 85%; 1H NMR (CDCl3) δ
7.68‐7.70 (d, J = 8.4 Hz, 2H), 7.56‐7.59 (d, J = 8.8 Hz, 2H) , 4.14‐4.20 (q, J = 7.2 Hz, 2H), 3.83‐3.86 (d, J =
13.6 Hz, 1H), 3.65‐3.69 (d, J = 13.6 Hz, 1H), 1.22‐1.25 (t, J = 7.2 Hz, 3H); 13C NMR (CDCl3) δ 164.4, 142.2,
132.6, 126.3, 125.8, 62.1, 61.5, 14.0; MS (ES+), m/z 290.9 (M+1) +; m.p. = 62‐63 °C.

General Experimental Procedure for Hydrolysis of Esters. Representative Procedure for
Hydrolysis of Methyl 2‐(Thiophen‐2‐ylsulfonyl)acetate (22e) (Scheme 1.3, reaction d): To a stirred
solution of methyl 2‐(thiophen‐2‐ylsulfonyl)acetate (22e, 115 mg, 0.52 mmol, 1 equiv.) in MeOH (5 mL)
and THF (1 mL) was added a solution of NaOH (209 mg, 5.22 mmol, 10 equiv.) in H2O (1 mL) dropwise.
The reaction mixture was heated and stirred at 50 °C for 5 h. Then the organic solvents were evaporated
and the mixture was diluted with 10 mL H2O. The solution was adjusted to pH 10 with NaOH (5 M
aqueous solution) and extracted with DCM (10 mL × 3). The aqueous phase was acidified to pH 2, and
further extracted with DCM (30 mL × 3). The organic phase was dried over Na2SO4, and the solvent was
removed to get 2‐(thiophen‐2‐ylsulfonyl)acetic acid (25a) as white solid (78 mg, 72%).

2‐(Thiophen‐2‐ylsulfonyl)acetic acid (25a). White solid; yield 72%; 1H NMR (CD3OD) δ 7.97 –
7.98 (d, J = 4.8 Hz, 1H), 7.79‐7.81 (d, J = 4.0 Hz, 1H), 7.22‐7.24 (m, J = 4.0 Hz, J = 4.8 Hz, 1H), 4.36 (s, 2H);
13

C NMR (CD3OD) δ 165.7, 141.2, 136.6, 136.5, 129.2, 62.9; MS (ES‐), m/z 205 (M‐1)‐; m.p. = 124‐126 °C.
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2‐(Phenylsulfonyl)acetic acid (25b). White solid; yield 86%; 1H NMR (CD3OD) δ 7.96‐7.98 (d, J =
7.6 Hz, 2H), 7.71‐7.75 (t, J = 7.6 Hz, 1H), 7.61‐7.65 (t, J = 8.0 Hz, 2H), 4.29 (s, 2H); 13C NMR (CD3OD) δ
165.7, 140.7, 135.4, 130.4, 129.7, 61.6; MS (ES‐), m/z 200 (M‐1) ‐; m.p. = 105‐107 °C.

Experimental Procedure for the Synthesis of 5‐(Bromomethyl)isoxazole (30) (Scheme 1.5,
reaction a): A mixture of 5‐methylisoxazole (29, 622 mg, 0.6 mL, 7.48 mmol, 1.0 equiv.), NBS (1.33 g,
7.48 mmol, 1.0 equiv.) and 2,2'‐azobis(2‐methyl‐propionitrile) (AIBN, 25 mg, 0.15 mmol, 2% equiv.) in
carbon tetrachloride (40 mL) was heated at reflux under irradiation with a tungsten light for 4.5 h. After
the solvent was evaporated, ethyl acetate was added (40 mL) and the solution was washed with H2O (5
mL × 2), brine (10 mL), and dried over Na2SO4. Evaporation of solvent afforded the crude product, which
was purified by column chromatography (Hex/EtOAc, 5:1) to give 5‐(bromomethyl)‐isoxazole (30, 480
mg, 40%) as colorless oil.

5‐(Bromomethyl)isoxazole (30). Colorless oil; yield 40%; 1H NMR (CDCl3) δ 8.22 (s, 1H), 6.33 (s,
1H), 4.50 (s, 2H).

General Experimental Procedure for Substitution Reaction Between Thiols and 2‐Bromo‐1,1‐
dimethoxyethane (33). Representative Procedure for Substitution Between Thiophene‐2‐thiol (18a)
and 2‐Bromo‐1,1‐dimethoxyethane (33) (Scheme 6, reaction a): A mixture of absolute ethanol (3 mL)
and sodium (152 mg, 6.6 mmol, 1.2 equiv.) in a dry flask was heated to reflux until the solution was clear
and cooled in an ice bath (under nitrogen). Thiophene‐2‐thiol (18a, 767 mg, 0.6 mL, 6.6 mmol, 1.2 equiv.)
was added at 0 °C under N2 and the reaction was stirred for another 15 min at 0 °C. Then 2‐bromo‐1,1‐
dimethoxyethane (33 ,97%, 930 mg, 0.67 mL, 5.5 mmol, 1.0 equiv.) was added and the reaction was
heated at reflux for 2 h. The solution was filtered and solvent was evaporated. Ethyl acetate (50 mL) was
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added and the solution was washed with H2O (8 mL × 2), saturated NaCl (8 mL), and dried over Na2SO4.
Evaporation of solvent gave the crude product which was purified by chromatography (Hex/EtOAc, 20:1)
to give 2‐(2,2‐dimethoxyethylthio)‐thiophene (34a, 538 mg, 48%) as colorless oil.

2‐(2,2‐Dimethoxyethylthio)thiophene (34a). Colorless oil; yield 48%; 1H NMR (CDCl3) δ 7.35‐
7.37 (dd, J = 1.2 Hz, J = 5.2 Hz), 7.17‐7.19 (dd, J = 1.2 Hz, J = 3.6 Hz, 1H), 6.97‐6.99 (t, J = 3.6 Hz, J = 5.2 Hz,
1H), 3.52‐3.54 (t, J = 5.6 Hz, 1H), 3.37 (s, 6H), 2.99‐3.00 (d, J = 5.6 Hz, 2H); 13C NMR (CDCl3) δ 134.0, 134.0,
129.6, 127.5, 103.3, 53.5, 40.9.

(2,2‐Dimethoxyethyl)(phenyl)sulfane (34b). Colorless oil; yield 59%; 1H NMR (CDCl3) δ 7.40‐7.42
(m, 2H), 7.28‐7.33 (m, 2H), 7.21‐7.23(t, 1H), 4.54‐4.57 (t, J = 5.6 Hz, 1H), 3.39 (s, 1H), 3.14‐3.15 (d, 5.6
Hz); 13C NMR (CDCl3) δ 136.1, 129.5, 129.1, 129.0, 126.3, 103.2, 53.6, 36.5.

General Experimental Procedure for Hydrolysis of Aldehyde Dimethyl Acetals (34).
Representative Procedure for Hydrolysis of 2‐(2,2‐dimethoxyethylthio)‐thiophene (34a) (Scheme 1.6,
reaction b): To a solution of 34a (113 mg, 0.55 mmol) in acetone (0.6 mL) was added 1% HCl (0.6 mL);
then the reaction was heated under reflux for 1.5 h. Solvent was evaporated and ethyl acetate (50 mL)
was added. The organic layer was washed with saturated NaHCO3 (8 mL), H2O (8 mL × 3), brine (8 mL),
and dried over Na2SO4. The evaporation of solvent afforded the crude product, which was purified by
column chromatography (Hex/EtOAc 6:1) to give 2‐(thiophen‐2‐ylthio)acet‐aldehyde (35a, 44 mg, 51%)
as light yellow oil.
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2‐(Thiophen‐2‐ylthio)acetaldehyde (35a). Light yellow oil; yield 51%; 1H NMR (CDCl3) δ 9.63‐
9.65 (t, J = 3.2 Hz, 1H), 7.40‐7.43 (m, 1H), 7.19‐7.20 (m, 1H), 7.99‐7.04 (m, 1H), 3.46‐3.49 (m, J = 3.2 Hz,
2H); MS (ES+), m/z 159 (M+1) +.

2‐(Phenylthio)acetaldehyde (35b). Colorless oil, yield 94%; 1H NMR (CDCl3) δ 9.54‐9.55 (t, J =
3.2 Hz, 1H), 7.25‐7.38 (m, 5H), 3.60‐3.61 (d, J = 3.2 Hz, 2H); MS (ES+), m/z 153 (M+1) +.

General Experimental Procedure for Synthesis of Aldoximes from Aldehydes (36).
Representative Procedure for Synthesis of 2‐(thiophen‐2‐ylthio)acetaldehyde oxime (36a) (Scheme 1.6,
reaction c): A mixture of 2‐(thiophen‐2‐ylthio)acetaldehyde (35a, 144 mg, 0.91 mmol, 1.0 equiv.),
hydroxylamine hydrochloride (95 mg, 1.37 mmol, 1.5 equiv.) and potassium bicarbonate (137 mg, 1.37,
1.5 equiv.) in MeOH (14 mL) was stirred at room temperature overnight. The solution was filtered and
solvent was evaporated. Then ethyl acetate (50 mL) was added and the solution was washed with H2O
(10 mL × 2), saturated NaCl (8 mL), and dried over anhydrous Na2SO4. Evaporation of solvent afforded
crude product which was purified by chromatography (Hex/EtOAc, 6:1) to give 2‐(thiophen‐2‐
ylthio)acetaldehyde oxime (36a, 106 mg, 67%) as light yellow oil.

2‐(Thiophen‐2‐ylthio)acetaldehyde oxime (36a). Light yellow oil; yield 67%; 1H NMR ((CD3)2CO,
mixture of isomers, ratio 1/1.5) δ 9.94, 10.31(s, 1H), 6.81‐7.59 (m, 4H), 3.53‐3.55, 3.72‐3.74 (d, 2H); MS
(ES+), m/z 174 (M+1)+.

2‐(Phenylthio)acetaldehyde oxime (36b). Colorless oil; yield 91%; 1H NMR ((CD3)2CO, mixture of
isomers, ratio 1/1) δ 10.49 (s, 0.5 H), 10.50 (s, 0.5H), 7.66‐7.98 (m, 5H), 7.33 (t, 0.5 H), 6.82 (t, 0.5 H),
4.36‐4.37 (d, 1H), 4.12‐4.13 (d, 1H); MS (ES+), m/z 168 (M+1)+.
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General Experimental Procedure for the Reduction Reaction. Representative Procedure for
Reduction of N‐(2‐(thiophen‐2‐ylsulfonyl)ethyl)‐hydroxylamine (38a) (Scheme 1.6, reaction e): To a
solution of 2‐(thiophen‐2‐ylsulfonyl)acetaldehyde oxime (37a, 46 mg, 0.22 mmol, 1.0 equiv.) in MeOH (2
mL) was added sodium cyanoborohydride (37 mg, 0.59 mmol, 2.68 equiv.); then the solution of 4.0 M
HCl in 1.4‐dioxane (0.2 mL) was added in three portions to maintain PH = 3.0 during the reaction time
(3.5 h). Then the solution of 5 N NaOH was added to adjust the pH to 11.0 and then solvent was
evaporated. Dichloromethane (50 mL) was added and the solution was washed with saturated NaCl (8
mL × 2), and dried over anhydrous Na2SO4. Evaporation of solvent afforded the crude product, which
was purified by column chromatography (Hex/EtOAc, 2:3) to give N‐(2‐(thiophen‐2‐ylsulfonyl)ethyl)‐
hydroxylamine (38a, 14 mg, 30%) as white solid.

N‐(2‐(Thiophen‐2‐ylsulfonyl)ethyl)hydroxylamine (38a). White solid, 30% in two steps; 1H NMR
(CDCl3) δ 7.73‐7.77 (m, 2H), 7.17‐7.19 (m, 1H), 7.53‐7.56 (t, J = 6.4 Hz, 2H), 3.37‐3.40 (t, J = 6.4 Hz, 2H);
13

C NMR (CDCl3) δ 140.2, 134.3, 128.1, 54.7, 47.6; MS (ES+), m/z 208 (M+1)+.

N‐(2‐(phenylsulfonyl)ethyl)hydroxylamine (38b). White solid; yield 38%; 1H NMR (CDCl3) δ 7.93‐
7.95 (m, 2H), 7.67‐7.71 (m ,1H), 7.57‐7.61 (m, 2H), 5.50 (br, 1H), 3.42‐3.45 (t, J = 6.0 Hz, 2H), 3.33‐3.36 (t,
J = 6.0 Hz, 2H); 13C NMR (CDCl3) δ 139.3, 133.9, 129.4, 128.0, 53.1, 47.3; 135.8, 129.1, 128.5, 126.0, 57.0,
30.0; MS (ES+), m/z 202 (M+1) +; m.p. = 67‐68 °C.
1.3.2

Whole cell AI‐2 inhibition assay in V. harveyi
All compounds tested were of high purity (about 98% with impurities being mostly solvents) as

judged by 1H‐NMR. The NMR spectra of all final compounds are provided in the Supplemental Section.
MM32 and BB886 strains of V. harveyi were purchased from ATCC (MM32 #BAA‐1121, BB886 #BAA‐
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1118). The quorum sensing assays were performed by following literature.8, 9, 14 In the AI‐1 bioassays,
cell‐free culture (5% of the test medium volume) from BB886 with OD600 of 0.8 ‐1.2 was added as the
source of AI‐1. Kanamycin (50 µg/mL) was used as antibiotics in incubation and inoculation.
1.3.3

Cytotoxicity assay in V. harveyi
Cell growth test (MM32)
Cell growth test was performed according to literature protocol.14 MM32 strain of V. harveyi

(ATCC #BAA‐1121) was grown for 16 h with aeration (175 rpm) at 30 °C in 2 mL of AB medium with
antibiotics (kanamycin 50 µg/mL and chloramphenicol 10 µg/mL). Then this bacterial culture was diluted
100‐fold with 20 mL AB medium in a 250 mL flask, tested compounds were added and incubated at
30 °C (175 rpm). The OD600 values were determined every 20 min. The doubling time was calculated
based on the OD600 values.

Plate counting test (MM32)
Plate counting test was performed on the basis of the MM32 test.9 MM32 bacteria were streak‐
seeded on fresh LM plates and then cultured in the presence of kanamycin 50 µg/mL and
chloramphenicol 10 µg/mL. Colonies appeared after overnight incubation at 30 °C. Single colonies were
picked from the LM plates and were grown for 16 h with aeration (175 r.p.m.) at 30 °C in 2 mL of
Autoinducer Bioassay (AB) medium10 with antibiotics (kanamycin 50 µg/mL and chloramphenicol 10
µg/mL). Then the solution was diluted to OD600 0.7 and the bacteria preinoculum was grown in AB‐Fe
medium with 1.2 mM of iron to a OD600 of 1.0‐1.1 with shaking at 30 °C (175 r.p.m.) for 1‐1.5 h.11 The
resulting inoculum culture was then diluted 5000‐fold in fresh AB medium. Solutions of the test
compounds in AB medium at concentrations ranging from 0 to 400 µM were prepared in 96‐well plates.
To these solutions, freshly synthesized DPD solution (pH 7) was added for a final concentration of 5 µM.
Boric acid was added to give a final concentration of 1 mM. After addition of bacteria in AB medium, the
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micro plates were covered with a non‐toxic plate sealer and incubated at 30 °C with aeration for 3‐5 h.
Light production was measured every hour using a Perkin‐Elmer luminescence microplate reader. The
bacteria solution incubated for 5 h in the presence of a compound at a concentration, which was close
to its IC50 was diluted to 1:100 and 1:1000, and plated onto fresh LM plates and incubated at 30 °C for
24‐48 h. The colonies appeared were counted. The concentration of bacteria, which yielded 30‐300
colonies was considered valid and CFU was recorded. The CFU (colony forming unit) ratio
(CFU1/2/CFUblank) and the luminescence ratio (Luminescence1/2/ Luminescenceblank) were compared.
1.4

Conclusions
In this study, structure optimization was performed with two hit compounds obtained from

virtual screening. Thirty nine new analogs were successfully synthesized and tested. Among all the
synthesized analogs, 12 were found to show good inhibition activity with IC50 values below 40 µM, 4 of
which showed single digit micromolar IC50 values, while 6 out of the 12 possess good selectivity toward
AI‐2 mediated quorum sensing. Overall, the following structural features are beneficial to AI‐2 inhibition
activities: a sulfone group (part B), “thiation” of the carbonyl group of part C, a hydrophobic group of
modest size in part D, and a biphenyl system in part A.
1.5
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2

A METHOD FOR RAPID AND SPECIFIC DNA POST‐SYNTHESIS MODIFICATION

Abstract:
Nucleic acids have been used in a number of applications such as therapeutic agents and
nanomaterials. Post‐synthesis modification of DNA is an important way of functionalizing DNA
molecules for extended applications. In this research, a method that enzymatically incorporates a
cyanobenzothiazole (CBT)‐modified thymidine has been described. The side chain handle CBT can
undergo a rapid and site‐specific cyclization reaction with 1,2‐aminothiols to afford DNA
functionalization in aqueous solution. Another key advantage of this method is the formation of a single
stereo/regioisomer in the process, which allows for precise control of DNA modification to yield a single
component.
2.1
2.1.1

Introduction
Therapeutic applications of nucleic acids
As one of the most important biomolecules, nucleic acids such as DNA and RNA are known to be

involved in the storage and transferring of genetic information. On the other hand, small interfering RNA
(siRNA)22 and microRNA (miRNA)23 were found to play important roles in post‐translational gene
regulations. In 1977, Paterson and co‐workers found that an exogenous oligonucleotide could inhibit
translation in a cell‐free system.24 Later Stephenson and Zamecnik showed that a short synthetic DNA
complementary to the Rous sarcoma virus 35S RNA could inhibit viral replication in the culture.25 These
“antisense” nucleic acids interfere with the translation by binding with the “sense” mRNA strand, either
sterically obstructing the ribosomes or forming a DNA‐RNA hybrid, which causes the selective cleavage
of the target mRNA by RNase H.26 The high specificity and low toxicity have suggested that antisense
mechanism could be especially useful in diagnostics and therapeutics.26‐28 Fomivirsen, which is an
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antisense drug inhibiting cytomegalovirus (CMV) replication, has been approved by US FDA in 1998 for
the treatment of CMV retinitis.29, 30
Besides antisense therapy, nucleic acid aptamers are emerging as promising therapeutic
agents.31‐33 Nucleic acid aptamers are DNA or RNA molecules that form complex three‐dimensional
structures and could bind to specific targets with high affinity. Aptamers are obtained from
combinatorial nucleic acid libraries through in vitro selection process termed SELEX (Systematic
Evolution of Ligands by Exponential Enrichment).34‐36 In this process, nucleic acid strands in the library
bound with the target were separated from the unbound to form an enriched library, which is subject to
amplification and subsequently another round of selection. Repeated positive selection process and
counter‐selection could ensure the binding affinity and specificity. The target of aptamer range from
small molecules such as theophylline,37 flavin mononucleotide (FMN)38 and adenosine triphosphate
(ATP),39 proteins such as thrombin,34 streptavidin40 and reverse transcriptase41 to complex systems such
as cell surface.42 These aptamers bind to their targets selectively with dissociation constants in the
nanomolar to micromolar range. Compared to antibodies which are relatively unstable and are raised
from time‐consuming in vivo approaches, nucleic acid aptamers exhibit advantages such as low‐cost
solid phase synthesis and easy chemical modifications. Therefore, aptamers show great potential in the
application of diagnostics and therapeutics. Pegaptanib, which is an RNA aptamer against vascular
endothelial growth factor (VEGF)‐165, has been approved by US FDA for the treatment of neovascular
age‐related macular degeneration (AMD).43
In addition to the therapeutic applications of nucleic acids in antisense and aptamer therapy,
the unique physical and chemical characteristics of DNA as genomic materials also make them very
useful for various other applications. For example, DNA has been explored for the application in
nanoarchitectures,44 nanorobots,45 nanocomputing,46 reaction encoding,47 and nanosensing.48 There is a
growing interest in the exploration of nucleic acids as therapeutic agents and novel nano‐materials.
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2.1.2

DNA post‐synthesis modifications through bioorthogonal reactions
Although research results and commercial availability of nucleic acid drugs are evidence for the

promising potential of nucleic acids as therapeutic agents, the clinical success has not been satisfactory.
First, nucleic acids are prone to degradation by nucleases in the biological environment. RNA molecules
are also unstable under basic conditions. Second, they show extremely poor membrane permeability
due to the highly charged backbone. These two properties decreased the bioavailability of unmodified
nucleic acids. Third, much less functional groups for binding are found in nucleic acids compared to
proteins and peptides. This might be one reason for the inefficient aptamer selection process. In
addition, for many applications, nucleic acids must be equipped with specific functionalities, such as
fluorescent markers, biotin, thiols, sugars, proteins, positively charged peptides (octaarginines), and
boronic acid for endowing different properties.49, 50 Therefore, tremendous efforts have been made to
modify nucleic acids in order to improve their bioavailability and functionality.
Typical strategies for nucleic acid modifications are shown in Figure 2.1. These strategies include 1)
changing the 2‐hydroxyl group on RNA to fluoro, amino or methoxyl groups or using methylene bridges
to lock the ribose structure (locked nucleic acids or LNA) in order to avoid degradation of RNA molecules;
2) backbone modifications such as using phosphorthioate instead of phosphordiester linkage to avoid
nuclease degradation; and 3) conjugation with other molecules. Oligonucleotide conjugation could be
done at 5’‐ or 3’‐ termini during or after solid‐phase synthesis because of their easy accessibility.51, 52
Recent research has found that modifications on C5‐ of thymine or C7‐of adenine could be well tolerated
by DNA polymerases, especially polymerases from the family B to form high‐density functionalized DNA
molecules.53‐55
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Figure 2.1 Strategies for nucleic acid modification
In our work of preparing modified DNA, we are especially interested in building boronic acid‐
functionalized DNA libraries for aptamer selection.50 It is well known that boronic acid as a Lewis acid
undergoes reversible covalent interactions with nucleophiles, especially 1,2‐ and 1,3‐diol structures,
which are commonly found on saccharides (Figure 2.1).56, 57 Previous work from our group has identified
a bis‐boronic acid that could selectively recognize Sialyl Lewis X (sLex) expressed on cancer cell surface.57

Scheme 2.1 Boronic acid‐diol interaction
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Glycosylation is one of the most important protein post‐translational modifications and is in‐
volved a variety of biological processes such as cell signaling and cell‐cell interactions.58 Altered protein
glycosylation patterns are implicated in a number of diseases such as diabetes59 and cancer.60,

61

Carbohydrate based biomarkers have been identified for many diseases.62‐65 However, protein
glycosylation is not directly encoded in the genome and is controlled by various factors. This has made
glycosylation extremely complicated and difficult to study. Due to their high binding affinity and
specificity, aptamers could be a useful tool for the study of glycosylation and thus possible diagnostic
and therapeutic agents for glycosylation‐related diseases. Considering the intrinsic affinity of boronic
acid to carbohydrates, it is conceivable that when DNA is modified with a boronic acid moiety, the
aptamer selection might be gravitate toward the glycosylation site and therefore for specific
differentiation of the glycosylation patterns.
Recent advances in bioorthogonal reactions (or “click” chemistry)49 such as Huisgen 1,3‐dipolar
cycloaddition has brought new strategies for DNA modification. Specifically, the labs of Seela66 and
Carell67 first reported the functionalization of DNA nucleobases through copper(I)‐catalyzed azide‐alkyne
cycloaddition (CuAAC) reaction, which was developed by Sharpless68 and Meldal.69 This protocol is highly
efficient and specific, and results in almost quantitative incorporation of different labels into the DNA.
While these seminal reports have allowed easy DNA modification, the CuAAC method has the issue of
copper‐catalyzed cleavage of DNA.49 In addition, Cu(I) also poses stability problems for some other
functional groups. For example, boronic acid was reported to be degraded during post‐synthetic
functionalization of DNA using CuAAC.70 Copper‐free chemistry has thus been used recently by different
researchers, including strain‐promoted azide‐alkyne cycloaddition,71 Staudinger ligation,72, 73 Diels‐Alder
reaction,74,

75

hydrazone76 and oxime77 formation, and native peptide ligation.51,

78

Although these

methods provide alternative ways for copper‐free DNA labeling, they still possess some limitations, e.g,
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low reaction rate, the need of other reagents/organic solvents for functionalization, as well as the possi‐
possibility of generating stereo/regioisomers.
In the previous studies our group has successfully demonstrated the synthesis and enzymatic
incorporation of C5‐boronic acid‐modified TTPs (B‐TTP) into DNA79‐81 (Figure 2.2). A series of B‐TTPs
(Compounds 43‐48) have been synthesized and successfully incorporated into DNA enzymatically
through primer extension or polymerase chain reactions (PCR).

Figure 2.2 Incorporation of boronic acid moiety into DNA through pre‐functionalized B‐TTP
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To explore solid‐phase synthesis of modified DNA and to avoid Cu(I)‐mediated degradation of
specific boronic acid we have also synthesized deoxyuridine phosphoramidite (49) bearing DIFO, a
strained alkyne handle82 to incorporate functional groups such as boronic acids through copper‐free
post‐synthesis modification (Figure 2.3).70 It was found that the copper‐free “click” chemistry could be
used reliably for DNA decoration. In addition to the ability to attach boronic acid moieties, other
functional groups could be incorporated. Therefore, DNA molecules with a “general” handle is superior
to the pre‐functionalized ones due to versatility and synthetic simplicity.

Figure 2.3 Incorporation of boronic acid moiety into DNA through solid‐phase synthesis and copper‐
free post‐synthesis modification

Although the previous work paved the way for enzyme‐catalyzed functionalization with a boronic
acid and the large scale synthesis of single stranded boronic acid‐modified DNA for further applications,
several limitations still need to be addressed, including the complex synthesis of different B‐TTP
moieties, Cu(I)‐mediated degradation of specific boronic acid functional groups, the potential problems
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during enzymatic recognition as well as multiple stereoisomers generated due to lack of symmetry. In an
attempt to circumvent these restrictions, and most importantly, to develop a novel platform for the
rapid and specific post‐synthesis modification of DNA that can address some limitations of current
methods, we are further interested in the strategy of enzyme‐catalyzed (such as PCR) synthesis of DNA
with a “general handle”, which can undergo a rapid and specific post‐synthesis functionalization.
Specifically, we need an approach that allows (1) high enzymatic incorporation efficiency of the “general
handle” modified nucleotide; (2) fast, site‐specific, and chemoselective post‐synthesis modification with
its reactive partner in aqueous solution; (3) high yield of a single stereochemically pure product. The last
point is especially important and remains a major obstacle for further application in DNA modification,
such as aptamer selection. Because even if the yield of the desired isomer is 90% at a single base, the
synthesis of a 90‐mer DNA would have the possibility of generating multiple isomers with random
distribution of regio‐/stereo‐isomers at different positions. In the present research, a method that
meets the above‐mentioned criteria for post‐synthesis modification of DNA is described.
2.2
2.2.1

Results and discussion
Synthesis of CBT‐modified deoxyuridine (CBT‐TTP) and labeling agents and kinetic study of the
cycloaddition reaction
To start this project, we first explored the well‐developed repertoire of biocompatible reactions

to find the appropriate reaction partners for highly reaction selectivity, absence of stereoisomers, and
compatibility with biological systems. The condensation of 1,2‐aminothiol with 2‐cyanobenzothiazole
(CBT) was chosen.83 This reaction, known as the last step of the bio‐synthesis of luciferin,83 has drawn
much attentions recently, largely due to the rejuvenation work of Rao84, 85 and Chin.86 In employing this
reaction for post‐synthesis DNA labeling, we have the option of either incorporating a 1,2‐aminothiol or
CBT into the nucleotide. We chose the pathway of making the CBT‐modified nucleotide, which does not
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involve protection/deprotection during the synthesis. In addition, the 1,2‐aminothiol also renders the
click‐labeling agent good solubility in aqueous solution. Based on the known fact that 5‐position
modification of deoxyuridine can be tolerated by polymerases and reverse transcriptases87 and our own
successful experience in developing a series of 5‐position boronic‐acid functionalized deoxyuridines,88
we plan to synthesize a CBT‐modified dUTP analogue (CBT‐TTP, 50) for enzymatic incorporation into the
DNA strand (Figure 2.4).
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Figure 2.4 Functionalization of DNA through enzymatic incorporation of CBT bioorthogonal handle and
cycloaddition reaction

CBT‐TTP (50) was prepared in 8 steps. Specifically, commercially available 1,4‐benzoquinone (51)
undergoes Michael addition reaction with L‐cysteine ethyl ester (52). Oxidative cyclization and ring‐
shrinking reaction yields ethyl 6‐hydroxybenzo[d]thiazole‐2‐carboxylate (55) in two steps.

89, 90

Propargylation, followed by ammonolysis and dehydration provided a modified CBT with terminal alkyne
moiety 58. Subsequent Sonogashira reaction yielded CBT‐T 59. Triphosphorylation was accomplished by
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the classical one‐pot three‐step method91 (Scheme 2.2) to provide CBT‐TTP (60) in 1.3% overall isolated
yield, which was then used for enzymatic incorporation.

Scheme 2.2 Synthesis of Compound 50 (CBT‐TTP)

The labeling agent, boronic acid‐modified cysteine analogue (Cys‐BA, 65) was synthesized in 4
steps (Scheme 2.3). According to literature procedures,92 commercial L‐cysteine was protected with
acetone and Boc protecting groups to form compound 62, which is then linked to the boronic acid
moiety through amide bond formation. Subsequent de‐protection steps yield Cys‐BA (65) in 55% overall
isolated yield.
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Scheme 2.3 Synthesis of Compound 65 (Cys‐BA)

Before the incorporation study, we studied the reaction profile. CBT has been reported to react
rapidly and specifically with 1,2‐aminothiol with a second‐order rate constant of 9 M‐1 s‐1.84 We reasoned
that CBT‐TTP would proceed in the same fashion. To confirm this, kinetic study using literature
methods136,137was performed for the reaction between the precursor CBT‐T (59, Scheme 2.2) and
cysteine. The reaction mixture was stirred at room temperature and monitored by HPLC at different
time points. The second‐order rate constant was determined to be 22 M‐1 s‐1 (Figure 2.5) under near
physiological conditions (phosphate buffer, pH = 7.4)).
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primer extension product using CBT‐TTP (Lane 6, Figure 2.6A) in place of dTTP gave a similar full‐length
DNA band as that of positive control with Klenow fragment and natural dNTPs only (Lane 5, Figure 2.6A).
Such results indicated that synthesized CBT‐TTP could be recognized similarly as dTTP by the Klenow
fragment, and incorporated into DNA.
After demonstrating the successful incorporation of CBT‐TTP, we further explored the feasibility
of post‐synthesis modification of DNA. The same 21‐nt template and 14‐nt primer without FAM label (5’‐
TAGCGGGTTGCTGG‐3’) were used. Synthesized Cys‐BA was used for the labeling of CBT‐DNA. As shown
from Figure 2.6B, fully extended product was observed using both dNTPs (Lane 1, Figure 2.6B) and CBT‐
TTP (Lane 2, Figure 2.6B). However, after being treated with Cys‐BA (1 mM, final concentration (50
equiv.), 30 min, supplemented with tris(2‐carboxyethyl)phosphine (TCEP, 1 mM final concentration))
with the primer extension product, only CBT‐DNA21 (CBT incorporated DNA product, 21nt) showed the
post‐synthesis product as expected (Lane 4, Figure 2.6B). The reduced mobility of Cys‐BA “click”‐labeled
CBT‐DNA21 indicated the reaction, which is presumably due to the interaction between boronic acid and
polyacrylamide matrix.70, 80 The result was further supported by the band with different mobility after
treating the Cys‐BA “click” labeled CBT‐DNA21 with H2O2 (1 mM final concentration, 1 h) (Lane 5, Figure
2.6B), which is due to the well‐known oxidation reaction of converting phenyl boronic acid functional
group into phenol group.93 As a control, the mobility for the dNTPs‐DNA21 (extended DNA product using
dNTPs, 21nt) band did not change after treating with Cys‐BA (Lane 3, Figure 2.6B), indicating no
reactions as expected.
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Figure 2.6 Primer extension and click labeling using CBT‐TTP.
A. Primer extension using CBT‐TTP catalyzed by Klenow fragment (3’‐5’exo‐), 20% PAGE analysis; B. Post‐
synthesis labeling using “click” reagent Cys‐BA, 20% PAGE analysis. 1) dNTPs‐DNA21, 2) CBT‐DNA21, 3)
dNTPs‐DNA21 + Cys‐BA, 4) CBT‐DNA21 + Cys‐BA, 5) Cys‐BA “Click” labelled CBT‐DNA21 treated with H2O2;

Understandably, mobility studies alone would not be enough to prove the post‐synthesis
modifications. MALDI‐MS was used to further examine the DNA products. Specifically, dNTP‐DNA21
treated with Cys‐BA (Lane 3, Figure 2.6B) had the same peak with m/z of 6518 (Figure 2.7B, calculated
[M+H]+: 6519, for MALDI spectrum please see Appendix) as the original DNA product. Such results
indicate that Cys‐BA does not interfere/react with dNTP‐DNA21, as expected. In contrast, full extension
of the primer using CBT‐TTP instead of dTTP yielded a CBT‐DNA21 (Lane 2, Figure 2.6B) with m/z of 6716
(Figure 2.7A, calculated [M+H]+: 6717) in MALDI‐MS. When treated with Cys‐BA, CBT‐DNA21 was
converted to a “click” labeled product (Lane 4, Figure 2.6B) with m/z of 6917 (Figure 2.7C, calculated [M‐
2H2O+H]+: 6917), corresponding to the Cys‐BA “click” labeled CBT‐DNA21 product. After treating the
“click” product (Lane 4, Figure 2.6B) with H2O2, a product (Lane 5, Figure 2.6B) with m/z of 6929 (Figure
2.7D, calculated [M+H]+: 6927), corresponding to the boronic acid oxidation product, was observed as
expected.70, 80 Such results confirmed the intended click‐modifications.
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Figure 2.7 MALDI spectra of DNA products.
A. dNTP‐DNA; B. CBT‐DNA; C. boronic acid modified CBT‐DNA; D. boronic acid modified CBT‐DNA treated
with H2O2.

Although C5‐position of thymine moiety is not involved in base paring, we were still interested in
the effect of a CBT and boronnic acid moiety on the thermostability of a DNA duplex. This was
investigated through a thermodenaturation study. Double stranded DNA21 prepared through Klenow
fragment (3’‐5’‐exo) was purified using Millipore Amicon 3k membrane filter and used for the
thermostability test in PBS buffer. Considering the reversible denaturation of dsDNA, the UV absorbance
of the cell was recorded while the temperature was decreasing by a rate of 0.5 °C/min. UV melting
curves are shown in Figure 2.8. The results (Table 2.1) have suggested that the incorporation of one CBT
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or boronic acid moiety in a 21‐bp DNA duplex only slightly decreased its stability (Tm decreased from
73.00 °C to 70.96 °C and 70.24 °C, respectively).

Figure 2.8 UV‐melting curves of DNA duplexes.
A. dNTPs‐DNA21, B. CBT‐DNA21, C. dNTPs‐DNA21 + Cys‐BA.

Table 2.1 Melting temperatures (Tm) of DNA dueplexes
DNA/Rounds
1
2
3
dNTPs‐DNA21
72.97
73.02
73.02
CBT‐DNA21
70.94
70.97
70.97
CBT‐DNA21 + Cys‐BA 69.87
70.92
69.92

4
72.97
70.97
70.92

Average
73.00 ± 0.03
70.96 ± 0.02
70.24 ± 0.59

After successful incorporation of one CBT moiety into DNA using Klenow fragment‐catalyzed
primer extension reaction, we further explored the feasibility of incorporating multiple CBT moieties.
Thus,

21‐nt

Template‐2

(5’‐TCAGTCACCAGCAACCCGCTA‐3’)

and

Template‐3

(5’‐

CACGACACCAGCAACCCGCTA‐3’) were designed to incorporate two and three CBT‐TTP, respectively. To
our surprise, the primer extension reaction catalyzed by Klenow fragment was unsuccessful due to
multiple incomplete bands, even at elevated temperature or longer reaction time (results not shown).
Knowing family B polymerases are relatively more tolerance to modified TTP,55, 94 a family B polymerase
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(KOD XL) from Thermococcus kodakaraensis, which is a mixture of the natural form and an exo‐ mutant,
was thus chosen instead for the reaction. As is shown in Figure 2.9A, the electrophoretic mobility of
modified DNA21 (lanes 2, 3 and 4) was further decreased with the incorporation of more CBT moieties.
This clearly indicated the successful incorporation of multiple CBT‐TTP into DNA through enzyme‐
catalyzed reactions. This was further confirmed by MALDI analysis of the incorporated product using
Template‐2 and Template‐3 (calculated [M+H]+ for Template‐2: 6929, found: 6930; calculated [M+H]+ for
Template‐3 7135, found: 7136, for MALDI spectrum please see Appendix). The extension product using
Template‐3 was further used for post‐synthesis modification by Cys‐BA. As is shown in Figure 2.9B, the
incorporated product (lane 2) could be successfully labeled by Cys‐BA, showing a slower‐moving band
(lane 3), which is consistent with the phenomena observed when using the template with one CBT
moiety incorporation.

Figure 2.9 Incorporation and post‐synthesis labeling of multiple CBT moieties.
A. Primer extension using CBT‐TTP catalyzed by KOD‐XL DNA polymerase, 20% PAGE analysis. 1)
Template‐1 with dTTP, 2) Template‐1 with CBT‐TTP, 3) Template‐2 with CBT‐TTP, 4) Template‐3 with
CBT‐TTP; B. Post‐synthesis labeling using extension product of Template‐3 amd “click” reagent Cys‐BA,
20% PAGE analysis, 1) dNTPs‐DNA21, 2) CBT‐DNA21, 3) CBT‐DNA21 + Cys‐BA.
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2.2.2.2

PCR amplification and click labeling
Encouraged by the successful incorporation of CBT‐TTP into short DNA sequences, we further

investigated the PCR amplification of a longer 90‐mer DNA strand.50 A 90nt ssDNA template (5’‐
CCTTCGTTGTCTGCCTTCGTGAGCGGAGTCAGACGCACGCTCGTACCTGTGCGCAAGCACTATGACGGACACCCTT
CAGAATTCGCACCA‐3’) was used in the PCR study. We first screened the incorporation using three
commercially available polymerases, including a family A polymerase from Thermus aquaticus (Taq) and
family B polymerases from Thermococcus litoralis (Deep VentR exo‐) and Thermococcus kodakaraensis
(KOD XL), which was used for primer extension experiments. As can be seen from the results
summarized in Figure 2.10, incorporation of CBT‐TTP were inefficient when using Taq (Lane 2, Figure
2.10) and Deep Vent (Lane 6, Figure 2.10). On the other hand, efficient incorporation was obtained by
using KOD XL polymerase, similar to the primer extension experiments for multiple CBT moieties
incorporation.

Figure 2.10 Enzyme screening for PCR incorporation of CBT‐TTP.
Lanes 1, 3, and 5 are using dNTPs, and lanes 2, 4 and 6 are using CBT‐TTP instead of dTTP. Lanes 1, 2:
Taq polymerase, 3, 4: KOD‐XL polymerase, 5, 6: Deep Vent (exo‐) Polymerase.

Since experiment has indicated that KOD XL could efficiently incorporate CBT‐TTP in both PCR
and primer extension reactions. Therefore, further studies were then conducted using KOD XL as the
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polymerase. Post‐synthesis labeling of the PCR product was explored using synthesized Cys‐BA and a
fluorescent labeling agent Cys‐FITC. As a negative control, no DNA product (Lane 1, Figure 2.10A) was
observed without using dTTP or CBT‐TTP. When the appropriate nucleotides are used, dNTPs‐DNA90
(DNA product using dNTPs, 90nt, Lane 2, Figure 2.10A) and CBT‐DNA90 (CBT incorporated DNA product,
90nt, Lane 3, Figure 2.10A) were obtained. This also indicated that CBT moiety‐containing DNA chains
could be used as templates for amplification. The all natural DNA 90‐mer showed different mobility from
that of CBT‐DNA90, presumably because of the added molecular weight of the latter. After post‐synthesis
modification with Cys‐BA (1 mM final concentration for 30 min, supplemented with 1 mM TCEP), a new
band with further reduced mobility was observed for the CBT‐DNA90 product (Lane 4, Figure 2.10A). As a
control, a band with the same mobility was observed after the subjection of dNTPs‐DNA90 to the same
treatment with Cys‐BA (Lane 5, Figure 2.10A). Such results demonstrated the feasibility of post‐synthesis
click‐modification with a longer 90‐mer DNA with multiple CBT moieties.
Finally, to further demonstrate the generality of this approach for post‐synthesis modification of
DNA. 1,2‐aminothiol conjugated FITC (Cys‐FITC) (Figure 2.10B) was used instead of Cys‐BA. The same
phenomenon was observed as with Cys‐BA. As can be seen from the EtBr channel in Figure 3C, which
stain all DNA products, no DNA product (negative control, Lane 1, Figure 2.10B) was observed without
using dTTP or CBT‐TTP. On the other hand, dNTPs‐DNA90 (Lane 2, Figure 2.10B) and CBT‐DNA90 (Lane 3,
Figure 2.10B) were observed with different mobilities. After post‐synthesis modification with Cys‐FITC (1
mM final concentration), supplemented with TCEP (1 mM final concentration) for 30 min, a new band
with further reduced mobility was observed (Lane 5, Figure 2.10B). As a control, dNTPs‐DNA90 was also
treated with Cys‐FITC under the same conditions. However, no mobility changes were observed after
treatment (Lane 4, Figure 2.10B). The successful post‐synthesis modification of CBT‐DNA90 was further
confirmed when imaging the same gel through the FITC channel, which only detects green fluorescein

61
signal. Only the band of Cys‐FITC labeled CBT‐DNA90 showed FITC signal, with no observable green fluo‐
fluorescein signals for all the other bands as expected.

Figure 2.11 “Click” labeling of PCR products.
A. “Click” labeling of dNTPs/CBT‐DNA90 with Cys‐BA (15% PAGE). 1) no dTTP, 2) dNTPs, 3) CBT‐TTP, 4)
DNA product after post‐synthesis modification of CBT‐DNA90 (lane 3) with Cys‐BA for 30 min, 5) DNA
yielded after post‐synthesis modification of dNTPs‐DNA90 (Lane 2) with Cys‐BA for 30 min; B. “Click”
labeling of dNTPs/CBT‐DNA90 with Cys‐FITC (15% PAGE). 1) no dTTP, 2) dNTP, 3) CBT‐TTP, 4) DNA
product after post‐synthesis modification of CBT‐DNA90 (lane 3) with Cys‐FITC 30 min, 5) DNA yielded
after post‐synthesis modification of dNTPs‐DNA90 (Lane 2) with Cys‐FITC for 30 min. The FITC channel
only detects DNA products with green fluorescence, while EtBr channel detects all DNA products.

From experimental results obtained above, it was demonstrated that CBT‐TTP could be
successfully incorporated into DNA strands through enzymatic primer extension and PCR reactions. The
CBT‐modified DNA obtained from extension and PCR reactions could undergo rapid and specific
cycloaddition with boronic acid and fluorophore‐modified cysteine analogues. This is a new approach for
DNA modification and could be used for DNA fluorescent labeling and aptamer selection.

62
2.3

Experimental section
General information
Solvents and reagents were purchased from VWR International, Oakwood Product Inc., or

Sigma‐Aldrich Co. and used without purification unless specified otherwise. When necessary, solid
reagents were dried under high vacuum. Reactions with compounds sensitive to air or moisture were
performed under argon. Solvent mixtures are indicated as volume/volume ratios. Thin layer
chromatography (TLC) was run on Sorbtech W/UV254 plates (0.25 mm thick), and visualized under UV‐
light or by a Ce‐Mo staining solution (phosphomolybdate, 25 g; Ce(SO4)2.4H2O, 10 g; conc. H2SO4, 60 mL;
H2O, 940 mL) with heating. Flash chromatography was performed using Fluka silica gel 60 (mesh size:
0.040‐0.063 mm) using a weight ratio of ca. 30:1 for silica gel over crude compound. 1H, 13C, and 31P‐
NMR spectra were recorded on a Bruker 400 spectrometer (400, 100, and 166 MHz, respectively) in
deuterated chloroform (CDCl3), methanol‐d4 (CD3OD), and DMSO‐d6 with either tetramethylsilane (TMS)
(0.00 ppm) or the NMR solvent as the internal reference. HPLC purification for CBT‐TTP was carried out
using a Shimadzu LC‐10AT VP system with a Zobax C18 reversed‐phase column (9.4 mm × 25 cm). The
sample was eluted (6 mL/min) with buffer A (20 mM triethylammonium acetate, pH 6.9‐7.1) and buffer
B (50% acetonitrile, 20 mM triethyl ammonium acetate) with the following: 0 min 0% B; 20 min 20% B;
30 min 100% B; 38 min 100% B; 40 min 0% B; and 45 min 0% B.
DNA primers and templates were purchased from Integrated DNA Technologies. Klenow
fragment (3’‐5’ exo), Taq. DNA polymerase, and Deep VentR (exo‐) DNA polymerase were purchased
from New England Biolabs. KOD‐XL DNA polymerase was purchased from Novagen, Darmstadt. Reaction
buffers were used as provided.
2.3.1

Synthesis of CBT‐TTP
Synthesis of Ethyl 6‐(prop‐2‐ynyloxy)benzo[d]thiazole‐2‐carboxylate 56
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To a solution of 55 (2.23 g, 10 mmol) in DMF (30 mL) was added K2CO3 (2.70 g, 20 mmol) and the
mixture was stirred at RT for 30 min. After addition of propargyl bromide (80% in toluene, 3.7 mL, 20
mmol), the reaction mixture was stirred at RT for 12 h before diluting with EtOAc (300 mL). Then the
mixture was washed with water (50 mL × 3) and brine (50 mL), and dried over Na2SO4. Solvent
evaporation followed by flash chromatography (Hex: EA, 4:1) gave a yellow solid (2.35 g, 90% yield). 1H
NMR (CDCl3): 8.14 (d, J = 9.1 Hz, 1H), 7.49 (d, J = 2.3Hz, 1H), 7.24 (dd, J = 2.3, 9.1 Hz, 1H), 4.80 (s, 2H),
4.55 (q, J = 8.7 Hz, 2H), 2.58 (s, 1H), 1.48 (t, J =8.7 Hz); 13C NMR (CDCl3): 160.7, 157.4, 156.4, 148.3, 138.4,
126.3, 117.9, 105.1, 63.0, 56.4, 14.3. HRMS (ESI) for C13H12NO3S [M+H]+ Calcd. 262.0545, Found
262.0544.

Synthesis of 6‐(Prop‐2‐ynyloxy)benzo[d]thiazole‐2‐carboxamide 57
To a solution of ester 56 (2.35 g, 9 mmol) in EtOH 100 mL was added ammonium hydroxide 40
mL. The reaction mixture was heated to 75 °C for 5 h and then cooled to RT. Solvent was removed using
a rota‐evaporator, and the resulting precipitate was filtered, washed with H2O, EtOH and EtOAc to give a
white solid (1.54 g, yield 73%). 1H NMR (CDCl3): 8.40 (s, 1H), 8.02 (d, J = 9.1 Hz, 1H), 8.00 (s, 1H), 7.81 (d,
J = 2.3Hz, 1H), 7.25 (dd, J = 2.3, 9.1 Hz, 1H), 4.91 (d, J = 2.2 Hz, 2H, ), 3.64 (t, J = 2.2 Hz, 1H); 13C NMR
(CDCl3): 163.7, 162.4, 157.3, 148.7, 138.9, 125.7, 118.3, 107.3, 79.8, 79.6, 57.1. IR film 3424.7, 3301.3,
1696.0, 1600.8, 1502.0, 1399.5, 1256.1, 1230.5; HRMS (ESI) for C11H9N2O2S [M+H]+ Calcd 233.0380;
found 233.0387.

Synthesis of 6‐(Prop‐2‐ynyloxy)benzo[d]thiazole‐2‐carbonitrile 58
To a suspension of amide 57 (1.1 g, 4.7 mmol) in anhydrous pyridine (25 mL) was added a
solution of phosphorous oxychloride (0.85 mL, 9.4 mmol) in CH2Cl2 (5 mL) dropwise at 0 oC. After stirring
at 0 oC for 1 h, the reaction was slowly warmed to ambient temperature and the resulting solution was
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stirred for an additional 12 h. CH2Cl2 (200 mL) was added, and the reaction was quenched by addition of
H2O 20 mL. The organic phase was separated, washed with H2O (20 mL × 2), brine (20 mL), and dried
over Na2SO4. Solvent evaporation followed by flash chromatography (Hex: EtOAc, 6:1) afforded
compound 58 as a light yellow solid (900 mg, yield 82%). 1H NMR (CDCl3): 8.13 (d, J = 9.1 Hz, 2H), 7.50 (d,
J = 2.5 Hz, 1H), 7.24 (dd, J = 2.5, 9.1 Hz, 1H), 4.82 (d, J = 2.4 Hz, 2H), 2.59 (t, J = 2.4 Hz, 1H); 13C NMR
(CDCl3): 158.2, 147.4, 137.2, 134.0, 126.0, 118.8, 113.1, 104.7, 56.5; IR film 3255.3, 2232.2, 2126.5,
1606.5, 1551.5, 1470.1, 1256.8, 1230.3, 1132.0, 1049.9, 127.7. HRMS (ESI) for C11H7N2OS [M+H]+ Cacld.
215.0279, Found 215.0289

Synthesis of CBT‐T 59
To a mixture of 5‐iodo‐deoxyuridine (708 mg, 2 mmol), Pd(PPh3)4 (230 mg, 0.2 mmol), and CuI
(76 mg, 0.4 mmol) in anhydrous DMF (12 mL) under argon was added DIPEA (0.62 mL, 4 mmol) followed
by a solution of compound 58 (700 mg, 3.0 mg) in DMF (4 mL). After stirring at RT overnight, DMF was
evaporated, and the remaining dark gum was purified by flash chromatography (DCM: MeOH, 20 : 1) to
afford compound 59 as a pale yellow solid (630 mg, yield 72%). 1H NMR (CD3OD): 8.38 (s, 1H), 8.07 (d, J =
9.2 Hz, 2H), 7.80 (d, J = 2.0 Hz, 1H), 7.33 (dd, J = 2.0, 9.2 Hz, 1H), 6.20 (t, J = 6.4 Hz), 5.05 (s, 2H), 4.38 (m,
1H), 3.92 (d, J = 3.2 Hz), 3.78 (m, 1H), 2.99 (s, 1H), 2.86 (s, 1H), 2.29 (m, 1H), 2.21 (m, 1H); 13C NMR
(CD3OD): 162.7, 158.3, 149.5, 146.9, 144.7, 137.2, 134.0, 124.9, 118.7, 112.6, 104.8, 97.6, 87.6, 86.8,
85.6, 79.0, 70.3, 60.9, 56.6, 40.2; IR film 3413.7, 2229.5, 1725.8, 1667.6, 1616.6, 1600.8, 1475.2, 1372.7,
1278.4, 1229.3, 1129.9, 1091.8, 1001.6; HRMS (ESI) for C20H16N4O6SNa [M+Na]+ Cacld 463.0683; Found
463.0674.
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Synthesis of CBT‐TTP 50
To a solution of CBT‐T 59 (70 mg, 0.16 mmol) and proton sponge (42 mg, 0.19 mmol, pre‐dried
in vacuum over P2O5 overnight) in anhydrous trimethylphosphate (0.6 mL) was added freshly distilled
POCl3 (18 µL, 0.19 mmol) dissolved in anhydrous trimethylphosphate (0.2 mL) dropwise via a syringe
with stirring under argon at 0 °C. The reaction mixture was further stirred in an ice‐bath for 2 h and then
a solution of tributylammonium pyrophosphate (226 mg, 0.48 mmol) and tri‐n‐butylamine (0.4 mL,) in
1.0 mL of anhydrous DMF was added in one portion. The mixture was stirred at RT for 10 min and then
triethylammonium bicarbonate solution (0.1 M, pH 8, 11 mL) was added. After stirring at RT for an
additional hour, the resulting reaction mixture was transferred to a 50‐mL centrifuge tube. Then EtOH
(33 mL) was added followed by 3 M NaCl solution (1.0 mL). After vortexing for 10 sec, the centrifuge
tube was placed at – 80 oC for 1 h, and then centrifuged at 5000 rpm for 20 min. After removing the
supernatant, the resulting pellet was purified by HPLC and lyophilized to give a pale yellow powder (9
mg, 10%). 1H NMR (D2O): 8.57 (s, 1H), 8.05 (d, J = 6.8 Hz, 2H), 7.65 (s, 1H), 7.27 (d, J = 9.2 Hz, 1H), 6.11 (t,
J = 6.4 Hz), 5.00 (s, 2H), 4.11‐4.13(m, 3H), 2.27‐2.31 (m, 2H); 13C NMR (D2O): 158.5, 151.5, 147.1, 146.0,
138.1, 135.7, 125.7, 119.9, 113.9, 106.2, 99.2, 88.9, 86.5, 86.4, 86.3, 79.5, 70.8, 65.8, 58.1, 58.0, 39.3,
17.5;
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P NMR (D2O) ‐10.9, ‐11.5, ‐23.4. HRMS (ESI) for C20H18N4O15P3S [M‐H]‐ Cacld. 678.9702; Found

678.9683.

2.3.2

Synthesis of cysteine‐bearing labeling agents
Synthesis of L‐(‐)‐(tert‐Butoxycarbonyl)‐2,2‐dimethylthiazolidine‐4‐carboxylic acid 13
Compound 62 was prepared starting from L‐cysteine hydrochloride (60) in two steps following

literature procedures.92
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Synthesis of compound 64
To a mixture of compound 62 (836 mg, 3.2 mmol), 63 (500 mg, 2.7 mmol), and HOBt (397 mg,
2.9 mmol) in anhydrous DCM (20 mL) and DMF (20 mL) under ice‐bath, was added Et3N (0.7 mL, 5.3
mmol) followed DCC (607 mg, 2.9 mmol) in one portion. The mixture was stirred at RT overnight and the
resulting solid was filtered off. The filtrate was concentrated under vacuum and the residue was purified
by flash chromatography (DCM: MeOH, 30:1) to afford intermediate 64. 1H NMR (CDCl3): 7.83 (d, J = 6.8
Hz, 2H), 7.25 (d, J = 6.8 Hz, 2H), 4.82 (brs, 1H), 4.48 (s, 2H), 3.25 (m, 2H), 1.82 (s, 3H), 1.77 (s, 3H), 1.50 (s,
6H).

Synthesis of Cys‐BA (65)
Compound 64 was stirred in DCM/TFA (20 mL/20 mL) at RT for another 2 h. Solvent was
evaporated under vacuum and the residue was treated with diethyl ether (100 mL). The resulting
precipitate was collected through filtration. After washing several times with diethyl ether, the collected
precipitate was dissolved in EtOH/H2O (300 mL/300 mL) with stirring for 30 mins. Evaporation of the
solvent yielded compound 65 as a white solid (497 mg, 73% in two steps). 1H NMR (CD3OD): 7.67 (d, J =
4.0 Hz, 2H), 7.25 (d, J = 4.0 Hz, 2H), 4.39 (m, 1H), 4.08 (m, 1H), 3.00 (m, 2H); 13C NMR (CD3OD): 168.2,
140.7, 134.9, 127.7, 55.8, 44.2, 26.1; HRMS (ESI) for C10H15BN2O3S [M+H]+ Cacld 255.0969; Found
255.0965.
2.3.3
2.3.3.1

Enzymatic incorporation and post‐synthesis labeling
General procedure for Klenow fragment catalyzed primer extension using dTTP or CBT‐TTP
The reaction mixtures of a final volume of 50 μL contained 21‐nt template (5’‐

GGTTCCACCAGCAACCCGCTA‐3’, 20 μM), 14‐nt primer or 5’‐FAM 14‐nt primer (5’‐(FAM)‐
TAGCGGGTTGCTGG‐3’, 20 μM), 10 mM Tris‐HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol at pH
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7.9, dATP, dCTP, dGTP, dTTP or CBT‐TTP at concentrations of 200 μM and 0.5 U μL‐1 Klenow fragment.
Reactions were performed by incubating the prepared solutions at 25 °C for 30 min. The primer
extension products were analyzed by 20% PAGE.
2.3.3.2

General procedure for KOD‐XL catalyzed primer extension using dTTP or CBT‐TTP
The reaction mixtures of a final volume of 50 μL contained 21‐nt template (Template‐2: 5’‐

TCAGTCACCAGCAACCCGCTA‐3’, Template‐3: 5’‐CACGACACCAGCAACCCGCTA‐3’, 20 μM), 14‐nt primer
(5’‐TAGCGGGTTGCTGG‐3’, 20 μM), 10 mM Tris‐HCl, 50 mM NaCl, 10 mM MgCl2, 1 mM Dithiothreitol at
pH 7.9, dATP, dCTP, dGTP, dTTP or CBT‐TTP at concentrations of 200 μM and 0.5 U μL‐1 KOD‐XL.
Reactions were performed by incubating the prepared solutions at 90 °C for 1 min, 20 °C for 1 min and
66 °C for 20 min. The primer extension products were analyzed by 20% PAGE.
2.3.3.3

Post‐synthesis labeling of the primer extension products CBT‐DNA21
The primer extension product CBT‐DNA21 was purified using Millipore Amicon 3 kDa spin column.

5 μL of 10 mM TCEP in PBS buffer was mixed with 25 μL of 2 mM Cys‐BA in 1 × PBS buffer. The reaction
was allowed to stand at RT for 10 min. Pre‐purified CBT‐DNA21 (20 μL) was then added to the mixture,
which was further incubated at 37 °C for 1 h. The negative control experiment was performed following
the same procedure except using dNTPs‐DNA21, the primer extension product using dNTPs and other
reagents. The resulting DNA products after post‐synthesis modification were purified with Millipore
Amicon 3 kDa spin column and analyzed by 20% polyacrylamide gel electrophoresis. For MALDI analysis,
the DNA product was further purified on a Sephadex G25 column. Fractions were collected and
concentrated using a Millipore Amicon 3 kDa spin column.
2.3.3.4

General procedure for PCR incorporation using dTTP or CBT‐TTP
The PCR mixture of a final volume of 50 μL contained DNA 90‐nt template (5’‐

CCTTCGTTGTCTGCCTTCGTGAGCGGAGTCAGACGCACGCTCGTACCTGTGCGCAAGCACTATGACGGACACCCTT
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CAGAATTCGCACCA‐3’, 10 nM), primer 1 (5’‐TGGTGCGAATTCTGAAGGGT‐3’, 1 μM), primer 2 (5’‐
CCTTCGTTGTCTGCCTTCGT‐3’, 1 μM), dATP, dCTP, dGTP, dTTP or CBT‐TTP at a concentration of 200 μM,
0.5 U μL‐1 DNA polymerase and 1 × reaction buffer as provided by vender. Ten thermal cycles were
conducted with melting at 90 °C for 20 s, annealing at 48 °C for 20 s, and extending at 72 °C for 30 s with
initial denaturing at 90 °C for 2 min and final extension at 72 °C for 5 min. The PCR products were then
analyzed by 15% PAGE.
2.3.3.5

Post‐synthesis labeling of the PCR product CBT‐DNA90

Post synthesis labeling of the PCR products was performed using similar procedures as those for
primer extension. Specifically, CBT‐DNA90 prepared from PCR was purified using Millipore Amicon 10 kDa
spin column. 5 μL of 10 m M TCEP was mixed with 25 μL of 2 mM Cys‐BA or Cys‐FITC and allowed to
stand at RT for 10 min. Pre‐purified CBT‐DNA90 (20 μL) was then added to the mixture, which was further
incubated at 37 °C for 30 min. The negative control experiment was performed following the same
procedure except using dNTPs‐DNA90, the PCR product using dNTPs and other reagents. The resulting
DNA product after post‐synthesis modification was purified with Millipore Amicon 10 kDa spin column
and analyzed by 15% PAGE.
2.3.4

Kinetic study of the reaction between CBT‐T and 1,2‐aminothiol (L‐cysteine)

Scheme 2.4 Reaction scheme of CBT‐T with L‐cysteine
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To a solution of CBT‐T 59 in acetonitrile was added a solution of L‐cysteine in PBS buffer (pH =
7.4) to afford the final concentration of CBT‐T (500 μM), L‐cysteine (550 μM) in a mixture of
acetonitrile/PBS buffer (v/v: 1/4). The resulting mixture was stirred at room temperature and monitored
by HPLC at different time points in a similar way as literature reported.95, 96 Applying similar kinetic
analysis reported in the references, 1/[CBT‐T] vs reaction time was plotted and the linear regression
analysis of 1/[CBT‐T] vs. time gave the second‐order rate constant as 22 M‐1. s‐1.
2.3.5

Thermodenaturization of duplex DNAs
The UV‐melting temperature studies were carried out by Cary 300 UV–Vis Spectrophotometer and

a temperature control module. Duplex DNA samples were prepared through Klenow fragment primer
extension reactions with dTTP or CBT‐TTP. Post‐synthetic sample was prepared by click reaction of CBT‐
DNA21 with Cys‐BA. All samples were cleaned using Millipore Amicon 10 kDa spin column. The samples
(1 µM DNA duplexes) were dissolved in PBS buffer (pH 7.4). The samples were heated to 80 °C and
cooled to 6 °C at a rate of 0.5 °C per min. 4 Rounds of melting were performed for each sample. The
melting temperature data and curves are presented in Table 2.1 and Figure 2.7.
2.4

Conclusions
Nucleic acids have been used in a number of new applications including therapeutics and

nanomaterial science. There is a critical need to develop chemistry that allows for the ready
functionalization of nucleic acid molecules. In the present research, a novel method for post‐synthesis
modification of DNA is described thorough the design, synthesis, and successful enzymatic incorporation
of a cyanobenzothiazole (CBT)‐modified TTP. The CBT‐TTP incorporated DNA products can undergo rapid
post‐synthesis modification via a biocompatible condensation reaction with 1,2‐aminothiol conjugated
boronic acid (Cys‐BA) or FITC analogue (Cys‐FITC). This approach provides a novel way for rapid and site‐
specific post‐synthesis modification of DNA without the issue of regio‐ or stereo‐isomers and the
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formation of a single isomer makes this approach suitable for DNA‐based aptamer selection work and
other applications.
2.5
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3

A FLUORESCENT PROBE FOR FAST QUANTITATION OF HYDROGEN SULFIDE

Abstract:
Hydrogen sulfide (H2S) has been recognized as one of the endogenous gasotransmitters, which
are produced in the cell and participate in a variety of cellular functions. However, the accurate
measurement of H2S in biological systems is still a challenge. We have developed dansyl‐azide (DNS‐Az)
as a fluorescent probe for H2S. In the presence of trace amount of sulfide anion, DNS‐Az is reduced into
sulfonamide quantitatively, which is excited at 340 nm and gives a strong fluorescence at around 500
nm. It has been proved to be very selective and efficient. Detection limit is about 1 µM in 20 mM
phosphate buffer (pH 7.5)/0.05% Tween‐20 (Buffer/Tween) and 5 µM in commercial bovine serum. This
probe has also been applied to the measurement of endogenous H2S in blood using C57BL6/J mice
model. The result obtained is consistent with the data obtained by using other methods. A new method
has been developed for the quantitative analysis of H2S in blood.
3.1
3.1.1

Introduction
Biological significance of hydrogen sulfide
Hydrogen sulfide (H2S) is a colorless gas with a strong odor of rotten eggs. It has a density (1.54

g/L) higher than air and good water solubility (4.0 g/L at 20°C). It dissociates in aqueous solutions in two
steps to HS‐ and S2‐ with a pKa1 of 6.9 and pKa2 of 12. Consequently, over 75% of H2S exists as
hydrosulfide (HS‐) at physiological pH. Naturally occurring H2S is produced from submarine hydrothermal
activity and marine biologic processes.97 H2S also results from industrial activities and residential waste
settings such as septic or sewer systems. It is well known as a toxic gas.98 Although the odor threshold
that can be detected by human nose ranges from 0.005‐0.3 ppm, exposure to over 100 ppm of H2S can
quickly cause olfactory paralysis.99, 100 Overexposure to this gas leads to unconsciousness, brain damage,
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or even death.101 However, H2S can be breathed at a low concentration (e.g. 20 ppm) without posing any
cumulative harmful effects.
Endogenous H2S is produced during cysteine (Cys) metabolism. Three main pathways for
enzymatic H2S synthesis have been discovered, including synthesis by cystathionine β‐synthase (CBS,
mainly localized in brain and liver),102 cystathionine γ‐lyase (CSE, mainly localized in liver),103 and
cysteine aminotransferase (CAT)/3‐mercaptopyruvate sulfurtransferase (3MST, mainly localized in
vascular endothelium and brain).104, 105 Since H2S is present in human brain106, 107 and blood108 in fairly
high concentrations (10‐150 µM), there have been intensive efforts in exploring the biological roles of
H2S. With the aid of various bio‐analytical techniques, H2S has been identified as one of the three
gasotransmitters,109, 110 joining nitric oxide (NO)111 and carbon monoxide (CO).112 H2S regulates the
respiration chain by inhibiting complex IV, cytochrome oxidase.113, 114 It also dilates blood vessels and
lowers blood pressure by acting as a smooth muscle relaxant and by opening the potassium dependent
ATP channel.115‐117 The signaling mechanism of H2S is through protein S‐sulfhydration, conversion of
cysteine –SH groups to –SSH.118‐121 The endogenous concentration of H2S is closely related to numerous
diseases,

including

cardiovascular

diseases,

Down

syndrome,122

and

lung

diseases.123

Endogenous/exogenous H2S was also found to show protective effects in the cardiovascular (CV)124 and
central nervous systems (CNS)125 and to play a dose‐dependent regulatory role in inflammation.126, 127
Therefore, the regulation of H2S levels is a possible drug development strategy.128, 129 Slow‐release H2S
donors are needed for a continuous low‐level production of H2S, and thus are useful in both research
and therapeutic applications.130‐133 More H2S donors with different mechanisms and tunable releasing
rates are needed for therapeutic applications. Thus, the selective detection and quantitation of H2S have
both diagnostic and therapeutic significance.
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3.1.2

Detection methods of hydrogen sulfide
Compared to other biologically important molecules, H2S is both volatile and reactive. It is very

easily oxidized by various oxidants. Therefore, the accurate detection of H2S depends heavily on the
experimental procedure, including sample preparation and detection methods. The analysis of H2S using
various methods results in markedly different conclusions. For example, endogenous concentrations of
H2S have been reported to be 50‐150 µM in most publications over the past two decades;106, 123, 134‐136
however, several recent studies have indicated that the concentration of free H2S is in the low
nanomolar range;137, 138 which is orders of magnitude lower than previously reported. Considering this
discrepancy in published data and due to the clinical relevance of H2S, accurate measurement of its
endogenous concentration is very important. Before the biological roles of H2S had been revealed, its
measurement primarily had applications in the environmental area. Sulfide detection was explored by
earth scientists for water analysis.97, 139 Nowadays, these methods have been modified for analysis in
biological systems. So far there have been three types of methods developed for the measurement of
H2S. These methods include chromatographic methods, electrochemical methods, and methods using
reactive colorimetric/fluorometric probes.
Gas chromatography (GC) is the most commonly employed chromatographic method.134, 140‐143
Specifically, H2S containing gas in the headspace of a sample or liberated from strongly acidic solutions
of sample preserve is injected into the GC column. After separation, it is detected by photoionization
detector (PID),143 flame photometric detector (FPD),141,

142

or pulsed flame photometric detector

(PFPD).140 For derived products, GC‐MS134 and high performance liquid chromatography (HPLC)144 have
also been employed in the detection of H2S. Because the additional separation step provides high
resolution with low background, chromatographic methods are able to selectively detect H2S with a very
low detection limit (pM‐nM). However, the use of chromatographic methods is limited because of its
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heavy reliance on instruments. In addition, multistep sample preparation is often required, which also
adds inconvenience to the analytical procedure.
Electrochemical methods include the use of either silver/sulfide selective membrane
electrodes145‐149 or polarographic methods.150, 151 These methods can provide nanomolar detection limits.
The advantages of electrochemical methods include high sensitivity, easy sample preparation, and
commercially available and inexpensive instruments. Disadvantages include long equilibration time, the
requirement of frequent reconditioning due to metal sulfide deposition on electrodes, and the inherent
problem of interference. The use of electrochemical methods in live systems is also limited.
Besides chromatographic and electrochemical methods, a colorimetric method, which takes
advantage of the reaction between H2S and N,N‐dimethyl‐p‐phenylenediamine, has been approved by
US Environmental Protection Agency (EPA) as a standard method for H2S quantitation in aqueous
solutions (Figure 1).152‐155 This reaction uses Fe3+ as the oxidant and forms a dye, methylene blue, as the
product, which absorbs intensely at 670 nm. This absorption change is used to quantitate H2S in solution.
The methylene blue method has a detection limit in the nanomolar range and has been used in a
number of studies for H2S quantitation in biological samples. However, dimers and trimers of methylene
blue are formed at concentrations higher than 30 µM, where a linear calibration curve cannot be
obtained. As a result, the quantitation of H2S at concentrations greater than 30 µM should be done using
diluted samples.
Because of the high sensitivity and the ability to conduct analysis in live systems, fluorescent
probes have found a wide variety of applications. A typical fluorescent probe functions through a
selective reaction, either reversible binding or irreversible conversion, with the target molecule to form
a product, which shows distinct absorption or fluorescence changes compared to the probe itself. The
change in absorption or fluorescence is then used for the detection or quantitation of the target
molecule. High selectivity of the sensing reaction allows for direct analysis without or with minimal
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sample preparations. The reaction rate is also a key factor because a fast reaction saves experimental
time and leads to efficient detection or even real‐time monitoring.
Due to the biological significance of H2S, the development of fluorescent probes for it fast and
accurate detection has become a very actively pursued area.156‐158 In this part of dissertation we report a
fluorescent probe (DNS‐Az) for fast and quantitative detection of H2S in aqueous solutions, including
bovine serum.
3.2
3.2.1

Results and discussion
Design and synthesis of a novel fluorescent probe for hydrogen sulfide
With the idea of developing a new method that will be useful for the rapid assay of hydrogen

sulfide concentrations under physiological conditions, we undertook the effort of searching for a
selective chemosensing agent for hydrogen sulfide. For easy use in a biology lab, the chemosensing
agent should (1) act fast (within seconds) under mild conditions, (2) be chemically stable for long‐term
storage, (3) be sensitive for detection under near physiological conditions, (4) show a linear
concentration‐signal relationship within physiologically relevant hydrogen sulfide concentration ranges
for easy quantitation, (5) show minimal or no interference by other anions in the blood serum, and (6)
be functional in aqueous solutions and blood plasma. Herein we report the development of a
fluorescent chemoprobe and its application in the determination of hydrogen sulfide in aqueous
solution, serum and whole blood.
Fluorescence is one of the most sensitive detection methods. Thus we were interested in
selecting a fluorophore, which has a high quantum yield, emits at a long wavelength, and responds to
hydrosulfide by fluorescent property changes. Dansyl is a commonly used fluorophore, and well known
for its strong fluorescence and long emission wavelength. We were interested in designing a sulfide‐
sensitive agent using this fluorophore by taking advantage of the known unique reduction of an azido

76
group by hydrogen sulfide.159 We reasoned that the reduction of an azido group attached to a strongly
electron‐withdrawing group would occur at an accelerated rate. Because of the difference in
electronegativity of the azido and amino groups and the added degree of rotational freedom for the
azido group, reduction of sulfonyl azide into sulfonamide should trigger a change in the electronic
properties and thus the fluorescent properties of the dansyl moiety.160 Therefore we synthesized dansyl‐
azide (DNS‐Az, 67, Scheme 3.1).161

Scheme 3.1 DNS‐Az (67) as a fluorescent probe for sulfide

The synthesis of DNS‐Az is simple with only one step from commercially available DNS‐Cl.
Sodium azide reacts fast with DNS‐Cl to yield the product nearly quantitatively. The product (67) is
purified through flash chromatography, and is ready for further evaluation for hydrogen sulfide
detection.
3.2.2

Evaluation of DNS‐Az as a fluorescent probe for hydrogen sulfide
Due to quenching effect of the azido group, DNS‐Az (67) by itself is non‐fluorescent. The

fluorescence quantum yield of DNS‐Az is 0.007 in acetonitrile (ACN). In order to evaluate DNS‐Az as a
fluorescent probe for hydrogen sulfide, Na2S was used as a hydrogen sulfide source. Upon addition of
Na2S, DNS‐Az solution showed a strong fluorescence enhancement. This fluorescence enhancement is
due to the formation of DNS‐NH2 (68), which is the reduction product. The identification of the product
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has been confirmed through NMR, HPLC and MS studies (for details please see experimental section).
DNS‐Az shows an absorption maxima at 358 nm (ε = 2930 M‐1cm‐1). When converted to DNS‐NH2, an 18
nm blue shift was found in the absorption spectra (Figure 3.1A). The fluorescent quantum yield of DNS‐
NH2 is 0.37 (Figure 3.1B). The changes in absorption wavelength and fluorescence quantum yield lead to
the fluorescence increase upon addition of Na2S.
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Figure 3.1 Absorption spectra of DNS‐Az and DNS‐NH2 and quantum yield test.
A. UV absorption spectra were recorded for DNS‐Az (67) (solid line) and DNS‐NH2 (68) (dashed
line) in acetonitrile at 100 μM, respectively, with acetonitrile as the blank reference; B. Fluorescence
quantum yield test of compounds 67 and 68.

The magnitude of the fluorescent enhancement was solvent‐dependent. When the experiments
were conducted in 20 mM phosphate buffer (pH 7.5)/ACN 1:1, 150 fold of fluorescent intensity
enhancement was observed with the addition 25 μM of sulfide. For a thorough understanding of the
solvent effect, we tested the following solvent systems: acetonitrile, deionized water, 20 mM sodium
phosphate buffer (pH 7.5), acetonitrile/water (1:1), acetonitrile/phosphate buffer (1:1), and 20 mM
sodium phosphate buffer (pH 7.5) with 0.05% Tween‐20 (Figure 3.2). The strongest response was
observed in acetonitrile with a maximum of 130‐fold fluorescent intensity increase with the addition of
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10 μM of sulfide. The solvent system that gave the smallest fluorescent intensity increases (about 8 fold)
was phosphate buffer or water alone. The presence of sodium phosphate buffer did not affect the
fluorescence intensity (Figure 3.2). Very interestingly, addition of 0.0
5% of Tween‐20, a commonly used additive in biological experiments as a buffer component, led
to a substantial increase in the magnitude of the fluorescent intensity change of DNS‐Az upon sulfide
addition. In such a mixed solvent, addition of 25 μM of sulfide led to a 40‐fold fluorescence

Fluorescence Intensity at 517 nm

enhancement. The detection limit was as low as 1 μM with a S/N of 3:1.
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With Sulfide

Figure 3.2 DNS‐Az fluorescence responses to sulfide in different solvent systems.
DNS‐Az 100 μM, Na2S 10 μM, λex = 340 nm, λem = 517 nm

The reaction time profile of DNS‐Az with sulfide was tested in different solvent systems. It was
found that the reaction completes very fast even in aqueous solutions. For example, the reaction
between 100 μM of DNS‐Az completes within 3 minutes in a mixed solvent of 20 mM phosphate buffer
and ACN (Figure 3.3A, B) or a 20 mM phosphate buffer with 0.05% Tween‐20 (Figure 3.3C, D).
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Figure 3.3 Reaction time scales in different solvent systems.
A,B. Reaction time profile in 20 mM phosphate buffer/acetonitrile 1:1 (DNS‐Az100 μM, H2S 30
μM); C,D. Reaction time profile in 20 mM phosphate buffer/0.05% Tween‐20 (DNS‐Az 100 μM, H2S 30
μM).

In order to study the selectivity of this chemoprobe for sulfide, the fluorescent properties of
DNS‐Az in the presence of various anions were examined in buffer/Tween. No comparable response was
observed from other anions (Figure 3.4). Since the detection is based on the reducing property of sulfide,
other possible reducing anions, such as iodide, bromide, fluoride, bisulfite, and thiosulfate, were also
tested. Totally 18 anions were screened, no obvious response was observed for most of the anions at 1
mM, a concentration that is 40 fold higher than that of sulfide. Among all the anions, only HSO3‐, S2O42‐,
and S2O52‐ led to some fluorescent intensity increases. However, the extent of the fluorescence increase
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was far smaller than those caused by sulfide even when the concentrations of those anions were 4‐fold
higher than that of sulfide (Figure 3.4B).

Figure 3.4 Selectivity test for DNS‐Az using different anions.
A. Comparison of fluorescence intensity changes of DNS‐Az solution with the addition of sulfide
and other anions; B. Fluorescence spectra of DNS‐Az upon addition of various anions (DNS‐Az 100 μM,
HSO3‐, S2O42‐, and S2O52‐ 100 μM; HS‐ 25 μM, all other anions 1 mM in 20 mM sodium phosphate buffer
(pH 7.5) with 0.05% Tween‐20, λex= 340 nm). Anions tested: Cl‐, Br‐, I‐, F‐, OH‐, OAc‐, CN‐, N3‐, NO2‐, HCO3‐,
HSO3‐, SO42‐, S2O32‐, S2O42‐, S2O52‐, HPO42‐, citrate.
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The response of DNS‐Az to other strong reducing agents, such as thiophenol, benzyl mercaptan
and cysteine were also tested. Benzyl mercaptan was the only one that showed strong enough respons‐
es (about 1/5 of that of sulfide at the same concentration, Figure 3.5), which could pose an interfering
problem. However, since benzyl mercaptan is rarely found in biological systems, this should not be a
practical issue. DNS‐Az was also found to be recalcitrant to the possible displacement reaction resulting
from attack by an amino group. It showed very limited response to glycine and lysine at concentrations
as high as 50 mM. This good selectivity for sulfide is very important and has indicated that the fluores‐
cent probe DNS‐Az could be used in complex biological systems for sulfide detection with minimal sam‐
ple pre‐treatment.
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Figure 3.5 Fluorescence response of DNS‐Az to other reducing agents and selected amino acids.
DNS‐Az 100 µM in 20 mM phosphate buffer/0.05% Tween‐20, λex= 340 nm, λem= 517 nm.

A linear relationship is always important for easy and accurate analysis. Thus, hydrogen sulfide
concentration‐dependent study was performed using both fluorometer and micro‐plate reader. The flu‐
orescence response of DNS‐Az to sulfide was studied in a variety of solvent systems, including ACN, a 1:1
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mixed solvent of 20 mM phosphate buffer with ACN and buffer/Tween. It was found that DNS‐Az reacts
with sulfide essentially quantitatively in both organic solvents and aqueous solutions. The fluorescence
intensity showed a reproducible linear relationship in buffer/Tween against hydrogen sulfide in all sol‐
vent system tested. When sulfide concentration is higher than that of DNS‐Az, the plot was found to
reach a plateau (results not shown), which means that the stoichiometry of this reaction was 1:1. Figure
3.6 shows a triplicated calibration curve obtained in Buffer/Tween using a 96‐well plate and a microplate
reader.
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Figure 3.6 Hydrogen sulfide calibration curve in buffer/Tween.
Fluorescence was determined using 96‐well plates: DNS‐Az 200 μM, Na2S 0‐100 μM in buff‐
er/Tween (excitation filter 340 nm, emission filter 535 nm).

DNS‐Az was found to be relatively stable under room light. However, it was found that pro‐
longed UV radiation (>5 min) enhanced the fluorescence intensity of DNS‐Az (Figure 3.7). As a result,
fluorescence intensity should be recorded using freshly made reaction mixture in order to obtain repro‐
ducible results. The observed increase in fluorescence most likely is due to reactions involving nitrene
generated under UV radiation. However, under normal experimental conditions, this is not an issue.
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Figure 3.8 Reaction time profile of DNS‐Az with sulfide in bovine serum.
DNS‐Az 100 μM, H2S 30 μM, λex= 340 nm, λem= 493 nm.

In order to further evaluate DNS‐Az as a fluorescent probe in blood serum, a triplicated calibra‐
tion curve was obtained in bovine serum using a 96‐well plate and a microplate reader. An excellent lin‐
ear relationship was also obtained in bovine serum (Figure 3.9). This calibration curve covers the range
of reported endogenous levels of hydrogen sulfide, indicating that this probe is very suitable for the de‐
tection of sulfide in biological samples. Due to the changes in the micro‐environment and the viscosity
of the medium, fluorescence intensity and emission wavelength is different when using different medi‐
um. For the samples that the medium is not readily available for calibration curve generation, a standard
addition procedure could be used for accurate measurement. Overall, the results suggest that the ani‐
ons and biological substrates normally encountered in the blood do not pose a problem in the quantita‐
tive detection of sulfide in a biological sample.
For a simple application, DNS‐Az was used to test the time dependent decay of hydrogen sulfide
in bovine serum. The extremely fast response of NDS‐Az toward sulfide allows accurate determination of
real‐time sulfide concentrations in bovine serum. When DNS‐Az was added at several different time
points after the addition of Na2S into bovine serum, the concentration of sulfide at each time points
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could be determined by comparing the fluorescence readings to a standard curve. The result is shown in
Figure 3.9B. It was found that sulfide has a very short half‐life (t1/2 ~5 min). This is due to fast metabo‐
lism of hydrogen sulfide in the serum.
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Figure 3.9 Detection of hydrogen sulfide in bovine serum.
A. Calibration curve of sulfide in bovine serum, fluorescence was determined using 96‐well
plates: DNS‐Az 200 μM, Na2S 0‐100 μM in commercial bovine serum (excitation filter 340 nm, emission
filter 535 nm); B. Time dependent decay of sulfide in bovine serum, sulfide 100 μM (initial concentra‐
tion), DNS‐Az (200 μM) was added at 0, 30, 60, 120, 300 and 660 s after addition of sulfide, fluorescence
intensity was tested using a fluorometer 3 min after the addition of DNS‐Az, λex= 340 nm, λem= 493 nm.

3.2.3

Determination of hydrogen sulfide concentration in mouse blood
Encouraged by the promising results obtained in phosphate buffer and bovine serum, we applied

this fluorescent chemoprobe to the determination of hydrogen sulfide concentrations in blood using
C57BL6/J mouse model (Figure 3.10). A standard addition procedure was used in the experiment. Zero
points were obtained through treatment of blood with ZnCl2 (1 mM final concentration). Standard Na2S
solutions were added into blood samples to a series of concentrations of 0, 10, 50, and 100 μM. The re‐
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sults obtained are shown in Table 3.1. The average sulfide concentration in mouse blood (n = 5) was de‐
termined to be 31.9 ± 9.4 μM, very similar to previous reported values in mouse plasma (34.1 μM).162
This has confirmed that our fluorescent chemoprobe can indeed be used into the detection of hydrogen
sulfide in real biological samples and the result is comparable with those obtained using current method.
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Figure 3.10 Detection of hydrogen sulfide in mouse blood.
Detection was performed using an internal standard method using C57BL6/J mice (n=5), deter‐
mined using 96‐well plates (DNS‐Az 200 μM, excitation filter 360 nm, emission filter 528 nm). Zero point
was obtained by trapping sulfide with ZnCl2 and calibration curve was obtained by using an internal
standard method. (Hydrogen sulfide 0, x, x+10, x+50, and x+100 μM). A. Sulfide concentration in mouse
1 (25.0 µM); B. Sulfide concentration in mouse 2 (30.2 µM); C. Sulfide concentration in mouse 3 (26.1
µM); D. Sulfide concentration in mouse 4 (48.4 µM); E. Sulfide concentration in mouse 5 (28.9 µM)

Table 3.1 Detection of hydrogen sulfide in mouse blood
Subject #
1
2
3
H2S (µM)

3.3

25.0

30.2

26.1

4

5

Average

48.4

28.9

31.9 ± 9.4

Experimental section
General information
All reagents were purchased from Aldrich. Thermometers were not calibrated. 1H NMR and 13C

NMR spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer. Mass spectral analysis
was performed on an ABI API 3200 (ESI‐Triple Quadruple). HPLC was performed on a Hewlett Packard
Series 1100 HPLC (column: Agilent Prep‐C18 5 μm, 4.6×250 mm). UV‐Vis absorption spectra were rec‐
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orded on a Shimadzu PharmaSpec UV‐1700 UV‐Visible spectrophotometer. Fluorescence spectra were
recorded on a Shimadzu RF‐5301PC fluorometer. 96‐Well plates were read and recorded on a Perki‐
nElmer 1420 multi‐label counter.
3.3.1

Synthesis and characterization of DNS‐Az and DNS‐NH2
Synthesis and characterization of of DNS‐Az (67)
A suspension of 66 (250 mg, 0.93 mmol) in 15 mL of EtOH was added dropwise into a stirred so‐

lution of sodium azide in 7 mL of a mixed solvent (H2O/EtOH, 1:1). Then the reaction mixture was stirred
at room temperature for 3 hr. The organic solvent was evaporated in vacuum, and the aqueous solution
was extracted by DCM. The combined organic layers was washed with brine and then dried over MgSO4.
Solvent evaporation gave the crude product, which was purified by flash chromatography to give 67
(107 mg, 42%) as a light yellow oil. 1H NMR (400 MHz, DMSO‐d6): 8.68‐8.66 (d, J = 8.4 Hz, 1H), 8.40‐8.38
(m, 1H), 8.07‐8.05 (d, J = 8.0 Hz, 1H), 7.77‐7.73 (m, 2H), 7.75 (s, 2H), 7.36‐7.34, (d, J = 7.8 Hz), 2.86 (s, 6H);
13

C NMR (100 MHz, CDCl3): 152.2, 133.7, 132.7, 130.1, 130.1, 129.7, 129.3, 123.0, 118.8, 115.9, 45.4; ESI‐

MS: m/z 277.1 (M+1)+.

Figure 3.11 HPLC chromatogram of DNS‐Az (67)

Synthesis and characterization of DNS‐NH2 (68)
A solution of sodium sulfide (43 mg, 0.18 mmol) in 0.4 mL H2O was added into a stirred solution
of 67 in 17 mL acetonitrile. The reaction mixture was stirred for 2 hr at room temperature. Then solvents
were evaporated under vacuum. The residue was purified by flash chromatography (DCM/MeOH 50:1)
to give pure DNS‐NH2 (40 mg, 91%) as a yellow solid. 1H NMR (400 MHz, DMSO‐d6): 8.44‐8.42 (d, J = 8.4

89
Hz, 1H), 8.30‐8.28 (d, J = 8.8 Hz, 1H), 8.13‐8.11 (m, 1H), 7.63‐7.56 (m, 2H), 7.59 (s, 2H), 7.27‐7.25, (d, J =
8.4 Hz), 2.83 (s, 6H);

13

C NMR (100 MHz, DMSO‐d6): 151.8, 140.2, 129.5, 129.4, 129.2, 128.0, 126.8,

124.0, 120.0, 115. 5, 45.5;m.p. 215‐217 °C; ESI‐MS: m/z 251.1 (M+1)+.

Figure 3.12 HPLC chromatogram of DNS‐NH2 (68)

3.3.2
3.3.2.1

Detection of hydrogen sulfide in aqueous solutions
Detection of hydrogen sulfide using a fluorometer
A stock solution (30 mM in ethanol) of DNS‐Az (10 µL, final concentration 300 µM) was added

into 1.0 mL of sample solution containing 0‐100 μM of hydrogen sulfide. Then it was mixed thoroughly
and incubated for 1‐5 min (depending on the reaction medium, for reaction time profile please see Fig‐
ures S6‐S8) and placed in a fluorometer for measurements with λex= 340 nm. The reading was then
compared to as tandard curve to obtain the concentration of hydrogen sulfide.
3.3.2.2

Detection of hydrogen sulfide using micro‐plate reader
A stock solution (50 mM in ethanol) of DNS‐Az (0.4 µL, final concentration 200 µM) was added

into 100 μL of samples in a 96‐well plate. Then the fluorescence intensity was measured on a micro‐
plate reader (excitation lamp filter 340 nm, emission filter 535 nm).The readings were then compared to
a standard curve to obtain the concentration of hydrogen sulfide. For analysis of sulfide in serum, it is
recommended that DNS‐Az be added immediately after sample preparation to avoid fast catabolism of
sulfide.
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3.3.3

Detection of hydrogen sulfide in mouse blood
DNS‐Az was dissolved in ethanol to make a stock solution of 50.0 mM. Male C57BL6/J mice 8 wk

of age were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were anesthetized with
ketamine/xylazine and blood was drawn with a syringe from the inferior vena cava of male C57BL6/J
mice (n = 5). These procedures were approved by the Institute for Animal Care and Use Committee at
Emory University School of Medicine and conformed to the Guide for the Care and Use of Laboratory
Animals, published by the National Institutes of Health (NIH Publication No. 86‐23, revised 1996), and
with federal and state regulations. Blood (100 µL × 4) was added into eppendorf tubes with DNS‐Az (0.4
µL, final concentration 200 µM). Na2S was spiked into each sample to a final concentration of 10, 50 and
100 µM. The samples were mixed thoroughly and centrifuged. Then 50 µL of serum was transferred
from each sample into a 96‐well plate. Zero point was obtained by trapping sulfide with ZnCl2 (1 µL in
100 µL blood, final concentration 1 mM) followed by centrifugation and addition of DNS‐Az into serum.
The plate was read on a micro‐plate reader (excitation lamp filter 360 nm, emission filter 528 nm).

3.4

Conclusions
In conclusion, a novel reduction‐sensitive fluorescence chemoprobe was developed for hydrogen

sulfide in aqueous solutions, including blood serum and whole blood. The probe was found to be very
selective for sulfide among 18 anions tested and other common reducing species, with a detection limit
of 1 μM in buffer/Tween and 5 μM in bovine serum with a signal‐to‐noise ratio of 3:1. The linear rela‐
tionship obtained in bovine serum covers the reported endogenous concentration range of hydrogen
sulfide. The probe was used in the detection of hydrogen sulfide in mouse blood using C57BL6/J mice
model. The result (31.9 ± 9.4 μM) was very close to the previously reported serum concentration of hy‐
drogen sulfide. In addition, the simplicity and ease in measurements and the compatibility of this probe
to 96‐well plates and a micro‐plate reader, which are readily accessible in biology labs, has made this

91
agent extremely easy to use. Hydrogen sulfide level in the biological system is tightly regulated and can
experience rapid changes in concentration. The unprecedented fast response by DNS‐Az (67) to hydro‐
gen sulfide allows it to be used for the detection of transient changes in sulfide levels without sample
pre‐treatment. The probe, DNS‐Az (67), is simple in structure, very easy to synthesize, stable and ame‐
nable to long‐term storage. A new research field has emerged in the past decade because of the newly
recognized significance of hydrogen sulfide as an endogenous gasotransmitter. The molecular mecha‐
nism of sulfide’s cellular actions remains to be understood, and novel H2S releasing drugs need to be
developed. We feel that this fast, selective, efficient and low‐cost detection method for sulfide will be
very useful in the booming research field of hydrogen sulfide. In addition, we are very pleased to see
more fluorescent probes being developed based on this redox mechanism.157, 158, 163‐167
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APPENDICES
Appendix A. 1H‐ and 13C‐NMR spectra of final compounds used in quorum sensing inhibition tests
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Appendix B. 1H‐ and 13C‐NMR spectra of intermediates in CBT‐TTP synthesis
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Appendix C. 1H‐ and 13C‐NMR spectra of DNS‐Az and DNS‐NH2
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